

FORM PTO-1396 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

19036/36959

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/719272

INTERNATIONAL APPLICATION NO.
PCT/JP99/03054INTERNATIONAL FILING DATE
07.06.99 (07 JUN 1999)PRIORITY DATE CLAIMED
08.06.98 (08 JUN 1998)

TITLE OF INVENTION

ANTIBODIES SPECIFIC FOR PHOSPHATASE SUBUNIT FOR LAR

APPLICANT(S) FOR DO/EO/US

YAMAMOTO, Hiroshi; TSUJIKAWA, Kazutake; UCHINO, Yukiko; and KONISHI, Noboru

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Substitute Sequence Statement Pursuant to 37 CFR 1.825(a) and (b)

Sequence Listing in computer-readable form

Return Receipt Post Card

J001 Rec'd PCT/PTO 08 DEC 2000

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR -

09/719272

INTERNATIONAL APPLICATION NO.

PCT/JP99/03054

ATTORNEY'S DOCKET NUMBER

19036/36959

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	39 - 20 =	19	x \$18.00
Independent claims	8 - 3 =	5	x \$80.00

\$342.00

\$400.00

Multiple Dependent Claims (check if applicable).

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,602.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

\$0.00

SUBTOTAL =

\$1,602.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$1,602.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

\$0.00

TOTAL FEES ENCLOSED =

\$1,602.00


Amount to be:
refunded \$
charged \$


- ☒ A check in the amount of **\$1,602.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **13-2855** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GASS, David A.
MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300


SIGNATURE
David A. Gass
NAME
38,153
REGISTRATION NUMBER
December 8, 2000
DATE



522 Rec'd PCT/PTO 12 JAN

PA
Attorney Docket No.: 19036/.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: YAMAMOTO,
H. *et al.*

Serial No.: 09/719,272

Filed: December 8, 2000


U.S. Natinal Phase of
International Application No.:
PCT/JP99/03054, filed June 7, 1999

For: ANTIBODIES SPECIFIC FOR
PHOSPHATASE SUBUNIT OF
LAR

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

I hereby certify that this paper is being
deposited with the United States Postal
Service with sufficient postage as first
class mail in an envelope addressed to:
Commissioner for Patents, Washington,
D.C. 20231 on January 10, 2001.


David A. Gass
Registration No. 38,153
Attorney for Applicants

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The Applicants request entry of the following amendment prior to
examination on the merits.

AMENDMENT

In the claims:

Please amend claims 39 as follows:

39. (Twice Amended) A method for diagnosis [diagnostic method
according to claim 29] of thyroid carcinoma [wherein a probe for LAR mRNA is used]
comprising the steps of:

measuring an expression level of LAR mRNA from thyroid tissue of a subject suspected of suffering from a thyroid carcinoma, and diagnosing the presence or absence of thyroid carcinoma from the expression level of LAR mRNA.


Remarks

The amendment to claim 39 is intended solely to place the claim in more conventional US form. The applicants reserve the right to re-introduce claims of the same scope in this application or in subsequent filings, such as divisional applications.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By:



David A. Gass
Registration No. 38,153
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 474-6300

January 10, 2001

#15

09/719272


PATENT

Attorney Docket No.: 19036/36959

J001 Rec'd PCT/PTO 08 DEC 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:) "EXPRESS MAIL"
) mailing label No. EM578442441US
YAMAMOTO, H. *et al.*)
) Date of Deposit: December 8, 2000
International Application No.:)
PCT/JP99/03054) I hereby certify that this paper (or fee) is
) being deposited with the United States Postal
Serial No.: Not yet assigned) Service "EXPRESS MAIL POST OFFICE
) TO ADDRESSEE" service under 37 CFR
Filed: Herewith) §1.10 on the date indicated above and is
) addressed to: Commissioner for Patents, Box
For: ANTIBODIES SPECIFIC) PCT, Washington, D.C. 20231
FOR PHOSPHATASE)
SUBUNIT OF LAR)
Group Art Unit: Not yet assigned)
Examiner: Not yet assigned)


Richard Zimmermann

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This amendment is being filed with the U.S. National filing of the above-identified PCT application. The Applicants request entry of these amendments prior to calculation of the filing fee and prior to examination on the merits.

AMENDMENTS

In the specification:

Please delete original Sequence Listing pages 1-19, and substitute therefor new pages 1-16 filed herewith, constituting an amended sequence listing.

09/719272

In the claims:

Please amend claims 4-7, 10, 12-13, 15-16, 19-20, 22, 24, 26, 28-29, 32-33, 35-36, and 38-39 as follows:

4. (Amended) The antibody according to [any of claims 1-3] claim 1, which is generated using a polypeptide encoded by a base sequence set out in SEQ ID NO: 1 or a fragment of said polypeptide as an antigen.

5. (Amended) The antibody according to [any of claims 1-4] claim 1 wherein the antibody is a monoclonal antibody.

6. (Amended) The antibody according to [any of claims 1-5] claim 1 wherein the antibody is generated using a fusion protein comprising a LAR phosphatase domain and another protein or a polypeptide fragment as an immunogen.

7. (Amended) The antibody according to [any of claims 1-5] claim 1 wherein the antibody is generated using a GST-LAR phosphatase domain fusion protein as an immunogen.

10. (Amended) The antibody according to [any of claims 6-9] claim 6 wherein the antibody that was generated using the fusion protein as an immunogen is screened using said fusion protein.

12. (Amended) The antibody according to [any of claims 5-11] claim 5 having a molecular weight of about 150 kDa.

13. (Amended) A hybridoma cell line that produces the antibody according to [any of claims 5-10 and 12] claim 5.

15. (Amended) A method for generating an antibody having specificity to a LAR phosphatase subunit, comprising a step of:

immunizing an animal with [wherein] a fusion protein comprising a LAR phosphatase domain and another protein or polypeptide fragment [is used as an immunogen].

16. (Amended) A method for generating an antibody having specificity to a LAR phosphatase subunit, comprising a step of:

immunizing an animal with [wherein] a GST-LAR phosphatase domain fusion protein [is used as an immunogen].

19. (Amended) The method according to [any of claims 15-18] claim 15, further comprising a step of:

screening antibodies generated in the immunizing step [wherein the antibody that was generated using the fusion protein as an immunogen is screened] using said fusion protein to identify an antibody having specificity to a LAR phosphatase subunit.

20. (Amended) A method of quantitative determination of LAR and/or LAR derived molecules comprising the step of:

determining an amount of LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain, which is contained in a test sample using the antibody according to [any of claims 1-12] claim 1.

22. (Amended) A method for quantitative determination of LAR and/or LAR derived molecules comprising the steps of:

isolating LAR and /or a fragment or a polypeptide that comprises at least a LAR intracellular domain, from a test sample using the antibody according to [any of claims 1-12] claim 1; and

measuring an activity of the isolated LAR and/or LAR derived molecules.

24. (Amended) A method for producing LAR and/or LAR derived molecules comprising the step of:
isolating LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain using the antibody according to [any of claims 1-12] claim 1.

26. (Amended) A method for identifying the presence of LAR and/or LAR derived molecules within tissue comprising the step of:
performing immunohistological examination using the antibody according to [any of claims 1-12] claim 1 to detect LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain.

28. (Amended) The antibody according to [any of claims 1-12] claim 1 having specific immunoreactivity to thyroid carcinoma cells.

29. (Amended) A method for diagnosis of thyroid carcinoma comprising the steps of:
taking a thyroid tissue specimen from a subject suspected as suffering from thyroid cancer; and
conducting diagnosis of thyroid cancer through evaluating immunoreactivity between the antibody according to claim 27 [or 28] and said tissue specimen.

32. (Amended) A composition for histological diagnosis of thyroid carcinoma comprising the antibody according to claim 27 [or 28].

33. (Amended) A DDS formulation that was targeted to thyroid carcinoma cells using the antibody according to claim 27 [or 28].

35. (Amended) The DDS formulation according to claim 33 [or 34] which is a pharmaceutical composition for diagnosis of thyroid carcinoma.

36. (Amended) The DDS formulation according to claim 33 [or 34] which is a pharmaceutical composition for therapy of thyroid carcinoma.

38. (Amended) The DDS formulation according to claim 36 [or 37] wherein the nucleic acid is an antisense nucleic acid or a ribozyme.

39. (Amended) A diagnostic method according to claim 29 of thyroid carcinoma wherein a probe for LAR mRNA is used.

Remarks

The filing fee has been calculated in view of the claim amendments herein. Support for the amended claims is found throughout the specification as originally filed, including in SEQ ID NO: 1 and claims 1-39 as originally filed.

The amendments to the Sequence Listing are intended solely to assure compliance with US PTO format requirements (37 CFR 1.821 et. seq.) and not to substantially change any sequences in any way.

The amendments to the claims are intended solely to place the claims in more conventional US form, eliminate improper multiple dependencies, and reduce the filing fee by reducing surcharges for excess claims. The applicants do not intend to narrow the scope of the claimed invention in any way, and reserve the right to re-introduce claims in this application or in subsequent filings, such as divisional applications.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By:



David A. Gass
Registration No. 38,153
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 474-6300

December 8, 2000

ANTIBODIES SPECIFIC FOR PHOSPHATASE SUBUNIT OF LAR**FIELD OF THE INVENTION**

The present invention relates to antibodies that specifically bind to a P-subunit, i.e., a phosphatase subunit, of LAR (leukocyte antigen related) protein, and particularly relates to the antibodies that specifically bind to an intracellular domain of LAR, and to methods for generation thereof. More particularly, the present invention provides antibodies that are useful for analysis and quantitation of protein tyrosine phosphatases, identification and isolation of LAR-related molecules, and medical drugs applicable to treatments such as therapy, prevention and alleviation as well as diagnosis of the disease states associated with insulin resistance.

BACK GROUND OF THE INVENTION

Mechanisms involving in the onset of arteriosclerosis have been gradually elucidated in these days, and risk factors thereof have been identified. Especially, hypercholesterolemia, hypertension, diabetes, and smoking are recognized to be manifest four risk factors, thus the therapeutic treatments have been extensively carried out. Clinically common pathologies of these disease states are insulin resistance. The meaning of insulin resistance is nearly equivalent to the reduction of sensitivity to insulin in cells, thereby the actions of insulin upon the uptake of sugar into the cells are deteriorated. The insulin resistance may be caused due to the abnormalities in secretion of insulin itself, abnormalities of insulin receptors on target cells, abnormalities of an intracellular signaling system, and reduced supply of sugar to the tissue based on peripheral circulatory disorder that is caused hemodynamically. Reaven, 1988, reports that many pathological states are developed due to the insulin resistance, and designates a pathological state as "syndrome X" that may concurrently represent insulin resistance, glucose tolerance abnormalities,

hyperinsulinemia, hypertriglyceridemia, hypo-HDL cholesterolemia and hypertension, and further suggests that the pathological state syndrome X closely participates in the onset of arteriosclerosis (Reaven, G. M. *et al.*, *Diabetes*, **37**, 1595-1607, 1988).

In addition, sugar supply to the cells is known to be generally decreased through insulin resistance, accompanied by enhancement of insulin secretion from pancreas, thus leading to hyperinsulinemia. Therefore, several problems in connection with insulin resistance have been raised in clinical fields. For example, insulin resistance and hyperinsulinemia are reported to promote diabetic nephritis (Niskanen, L. *et al.*, *Diabetes*, **41**, 736-741, 1993), and to elevate frequency of diabetic retinopathy (Yip, J. *et al.*, *Lancet*, **341**, 369-370, 1993). Moreover, insulin resistance has been reported to enhance plasminogen activator inhibitor 1 (PAI-1), to deteriorate the functions of a blood fibrinolytic system (Potter van Loon BJ *et al.*, *Metab. Clin. Exp.*, **42**, 945-954, 1993), and to trigger arterial atherosclerosis (Sato, Y. *et al.*, *Diabetes*, **38**, 91-96, 1989).

Prevalence rate of diabetes accounts for 5% of the total population, and approximately six millions of Japanese citizens are suffering from diabetes. Diabetes comprises insulin dependent diabetic mellitus (IDDM) and insulin independent diabetic mellitus (NIDDM). Reportedly, IDDM accounts for about 7% of the total diabetes cases, whilst NIDDM does about 90%. In particular, a significant causative factor of the onset of NIDDM that corresponds to a majority of diabetes has been conceived as the insulin resistance.

To date, tyrosine phosphorylation has been elucidated to play important roles in signal transduction of insulin. Insulin receptor is a hetero-tetramer of two glycoprotein subunits, namely an α -subunit having a molecular weight of 135 kDa and a β -subunit having a molecular weight of 95 kDa, which are bound through disulfide bonds resulting in $\alpha_2\beta_2$ structure. The α -subunit has an insulin binding activity, while the β -subunit has a protein tyrosine kinase (PTK) domain that is activated by

autophosphorylation. Accordingly, when insulin is bound to the α -chain of an insulin receptor, certain tyrosine residues existing in the β -chain of the insulin receptor are autophosphorylated. The activity of insulin receptor tyrosine kinase is further promoted through the tyrosine autophosphorylation. It is reported that thus activated insulin receptor tyrosine kinase phosphorylates tyrosine residues of IRS (insulin receptor substrate), the intracellular substrates thereof, and signal transduction is proceeded through recognition and binding of the tyrosine-phosphorylated insulin receptors by Ash/Grb2 or PI-3 kinase, finally resulting in manifestation of biological activities of insulin, such as glucose uptake, sugar metabolism and cell proliferation (see, Fig. 9, Goldstein, B.J. *et al.*, *Receptor*, **3**, 1-15, 1993; and Kanai, F. *et al.*, *Biochemical and Biophysical Research Communications*, **195**(2), 762-768, 1993). In this signal transduction pathway, however, an enzyme tyrosine phosphatase, which inactivates the activated insulin receptors, i.e., protein tyrosine phosphatase (hereinafter referred to as PTP), has not been progressively studied.

The serious studies of PTPs were initiated after completion of cloning of PTP1B gene and elucidation of the nucleotide sequence thereof by Fischer *et al.* in 1988, which is cytoplasmic PTP derived from human placenta (Tonks, N. K. *et al.*, *J. Biol. Chem.*, **263**, 6722-6730, 1988; Charbonneau, H. *et al.*, *Proc. Natl. Acad. Sci. USA*, **85**, 7182-7186, 1988). Consequently, homology to PTP1B could be observed not with the known serine/threonine phosphatases but with two cytoplasmic regions of CD45, a transmembranous molecule involved in a hemopoietic system. Moreover, CD45 was also revealed to have PTP activity (Tonks, N. K. *et al.*, *Biochemistry*, **27**, 8695-8701, 1988; and Charbonneau, H. *et al.*, *Proc. Natl. Acad. Sci. USA*, **85**, 7182-7186, 1988).

To date, many PTPs have been cloned based on their homologies of cDNA sequences, and new PTPs have been reported subsequently (Streuli, M. *et al.*, *J. Exp. Med.*, **168**, 1523-1530, 1988; Krueger, N. X. *et al.*, *EMBO J.*, **9**, 3241-3252, 1990; and

Amended under PCT Art. 34(2)(b)

JC01 Rec'd PCT/PTO 08 DEC 2000

Trowbridge, I. S. *et al.*, *Biochim. Biophys. Acta*, **1095**, 46-56, 1991). PTPs can be classified generally to: (1) membrane type PTPs having transmembrane region (LAR, leukocyte common antigen, namely CD45, as well as PTP α , β , γ , δ , ϵ and ζ), and cytoplasm type PTPs without transmembrane region (PTP1B, TC-PTP, PTP-MEG, PTPH1, STEP and PTP1C).

Many of membrane type PTPs have two PTP homologous domains inside the cell (domain 1 and domain 2, see, Fig. 1(a) and (b)). A sequence comprising cysteine (signature motif), Ile/Val-His-Cys-Xaa-Ala-Gly-Xaa-Xaa-Arg-Ser/Thr-Gly (SEQ ID NO: 2), has been conserved in the phosphatase domains between the PTPs reported heretofore. The research on crystallography of PTP1B revealed that the region forms small pockets on the surface of a PTP molecule, and that the cysteine residue is located to the bottom of the pocket, participating directly in binding of the molecule to phosphate (Barford, D. *et al.*, *Science*, **263**, 1397-1404, 1994). In addition, it was also revealed that the depth of the pocket of PTP may determine the specificity of serine/threonine phosphatase because phosphate that is binding to serine or threonine cannot reach to the pocket of the enzymatic active center of PTP1B. Moreover, the importance of the above-mentioned signature motif in exhibiting the enzymatic activity has been elucidated (Streuli, M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990). Taking into account of these observations, it has been conceived that the conserved cysteine in domain 1 may play an important role in exhibiting the enzymatic activity, and domain 2 may determine the substrate specificity of the enzyme.

Among a group of PTPs, LAR derived from human is a prototype of receptor type protein tyrosine phosphatases, which was cloned from human placental genome library using a phosphatase domain of CD45, a receptor type protein tyrosine phosphatase, as a probe (Streuli M. *et al.*, *J. Exp. Med.*, **168**, 1553-1562, 1988). CD45 is specifically expressed on hemocytic cells, whilst LAR is expressed on the cells other than hemocytic cells, particularly in insulin sensitive organs such as liver and skeletal muscle (Goldstein B.

J., *Receptor*, **3**, 1-15, 1993). LAR is especially interesting among many types of receptor type PTPs due to its similarity of the extracellular domain with cell adhesion molecules. The entire structure of LAR is elucidated as having 150 kDa of extracellular E-subunit that consists of Ig-like domains and fibronectin type III domains, and 85 kDa of P-subunit comprising a transmembrane region and an intracellular domain having two phosphatase domains, which are covalently bound immediately outside of the cell membrane (see, Fig. 1, Streuli M. *et al.*, *EMBO J.*, **11**, 897-907, 1992).

A large number of functional roles of LAR have been reported to date. For example, it was reported that: responses to neurotrophin are decreased in LAR deficient nerves (Yang, T. *et al.*, 27th Annual Meeting of the Society for Neuroscience, New Orleans, Louisiana, USA, October 25-30, 1997, Society for Neuroscience Abstracts, **23**, 1-2, 1997); secretion of apolipoprotein B is decreased by suppression of LAR activity (Phung, T. L. *et al.*, *Biochemical and Biophysical Research Communications*, **237**(2), 367-371, 1997); and loss of expression of LAR diminishes the size of cholinergic nerve cells of prosencephalon basement, thus control by the cholinergic nerve cells at hippocampal dentate gyrus is deteriorated (Yeo, T. T. *et al.*, *J. Neurosci. Res.*, **47**(3), 348-360, 1997). In such a manner, it has been gradually revealed that LAR is bearing several important roles in a living body. Furthermore at present, the most remarkable researches are directed to the relationships between LAR and insulin receptors (Hashimoto, N. *et al.*, *J. Biol. Chem.*, **267**(20), 13811-13814, 1992).

In 1995, a literature was presented which should be noted, reporting that LAR tyrosine phosphatase activity is abnormally increased in adipose tissue of an obese person, with such an increase being suggested as a cause of onset of insulin resistance and a risk factor of cardiovascular diseases (Ahmad, F. *et al.*, *J. Clin. Invest.*, **95**(6) 2806-2812, 1995). Several reports followed thereafter illustrating that LAR is closely concerned with insulin receptors (Mooney, R. A. *et al.*, *Biochemical and Biophysical Research Communications*,

235(3), 709-712, 1997; Orr, S. R. *et al.*, *Biochemical Society Transaction*, **25**(3), 452S, 1997; Ahmad, F. *et al.*, *J. Clin. Investigation*, **100**(2), 449-458, 1997; Ahmad, F. *et al.*, *J. Biol. Chem.*, **272**(1), 448-457, 1997; Norris, K. *et al.*, *Febs Letters*, **415**(3), 243-248, 1997; and Li, P. M. *et al.*, *Cellular Signaling*, **8**(7), 467-473, 1996). Further, on the basis of such information, Ahmad, F. *et al.* recently reported that PTP1B may be a therapeutic target of disease states involving in insulin resistance (Ahmad, F. *et al.*, *Metabolism, Clinical and Experimental*, **46**(10), 1140-1145, 1997). From the researches to date on PTPs such as LAR, CD45 and the like, it has been elucidated that PTPs bear extremely important roles in an intracellular signaling system.

In 1992, Streuli *et al.* reported that binding between LAR E-subunit and P-subunit may be dissociated due to the noncovalency of their binding, and thus E-subunit is specifically shed from the cell membrane surface (Streuli, M. *et al.*, *EMBO J.*, **11**(3), 897-907, 1992). However, because many researchers have focused the studies using polyclonal or monoclonal antibodies elicited against a LAR E-subunit that is an extracellular domain thereof, a P-subunit even solely having phosphatase activities has been ignored. For example, when an anti-LAR antibody is used intending measurement of LAR phosphatase assay, total phosphatase activity could not be measured unless an antibody to P-subunit is employed. In view of such circumstances, the present inventors started to produce antibodies that specifically bind to a LAR P-subunit, particularly to an intracellular domain thereof, without any specificity to CD45.

Known antibodies to protein tyrosine phosphatase include an antibody generated using 196 amino acid residues as an antigen spanning from the transmembrane region of CD45 to a part of phosphatase domain 1 (Transduction Laboratories). However, it is unclear how these antibodies are immunospecific to phosphatase domains of LAR and the other protein tyrosine phosphatases. Therefore, it was also necessary to produce antibodies which are specific to a LAR intracellular

Amended under PCT Art. 34(2)(b)

domain but not to CD45.

Thyroid tumors include benign adenoma and malignant carcinoma. At present, palpation, ultrasonic diagnosis, fine needle aspiration cytology, and diagnosis on tissue sections are clinically carried out in order to diagnose thyroid tumors. Thyroid tumors can be classified into adenoma, papillary carcinoma, follicular carcinoma, undifferentiated (anaplastic) carcinoma, medullary carcinoma and malignant lymphoma, whilst thyroid carcinoma (papillary and follicular cancers) can be generally classified into differentiated and poorly differentiated types.

On diagnosis of thyroid carcinoma, if abnormalities were found on palpation and ultrasonic diagnosis, cytological examination with fine needle aspiration has been predominantly carried out because of fewer burdens to the patient, and in difficult cases where definite diagnosis is impossible, additional histological diagnosis is carried out in which thyroid tissue is excised. However, such histological diagnosis imposes more burdens to the patient, and there exist possibilities to excise together with normal tissue. In fact, discrimination by cytological examination is often difficult to draw exact diagnosis, thus many cases have been nevertheless entrusted to histological examination. Additionally, fine needle aspiration cytology does not result in definite diagnosis because cell-cell bindings may be destroyed in those specimens compared to the morphologic observation on tissue sections. Furthermore, in almost cases of follicular carcinoma, discrimination between benign and malignant tumors can be difficult even though histological diagnosis is performed as well as cytological examination. Accordingly, it has been strongly desired by clinicians or pathologists to develop new tools that can discriminate benign/malignant tumors in fine needle aspiration cytology even in such difficult cases for diagnosis as in follicular carcinoma.

Amended under PCT Art. 34(2)(b)

SUMMARY OF THE INVENTION

One aspect of the present invention is to provide an antibody that specifically binds to a phosphatase subunit of LAR, particularly an antibody that specifically binds to an intracellular domain of LAR. Further, in accordance with the present invention, an antibody is provided that specifically binds to an intracellular domain of a LAR phosphatase subunit, without specificity to other protein phosphatases.

The antibody may be preferably generated using a polypeptide corresponding to an intracellular domain of LAR, encoded by a nucleotide sequence set forth in SEQ ID NO: 1 or any of fragments thereof as an antigen. Further, preferred antibody may be a monoclonal antibody because of its immunospecific property.

Such an antibody may be generated using a fusion protein comprising a LAR phosphatase domain and another protein or a polypeptide fragment, as an antigen. As the another protein or a polypeptide fragment to be a member of the fusion protein, GST (glutathione-S-transferase) may be particularly suitable, besides, polyhistidine (preferably 6 histidine residues), calmodulin binding peptide (CBP), protein A may be employed.

When polyhistidine is employed, absorption to nickel-chelating resin can be utilized for isolation and purification of the fusion protein expressed by a gene recombinant process, wherein addition of EDTA or imidazole substance as well as pH change may be adopted for dissociating the protein from the resin. When CBP is employed, the expressed fusion protein may be subjected to an affinity chromatography using calmodulin affinity resin, and then may be dissociated from the resin by adding EGTA. In addition, when protein A is employed, the expressed fusion protein may be subjected to an affinity chromatography using IgG sepharose (e.g., IgG Sepharose 6FF), and then may be dissociated from the resin by changing pH.

Moreover, another candidate for a protein or a polypeptide fragment to be employed in the fusion protein may include for example, Xpress, Thioredoxin, c-myc, V5, HA/c-myc and the like. For isolation and purification of the intended fusion protein with a LAR phosphatase domain, expression of the protein may be followed by subjecting to an antigen-antibody affinity column.

The aforementioned preferable immunogen of the present invention, namely a fusion protein of GST and a LAR phosphatase domain, may be suitably produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours, preferably at 23-25°C for 18 hours; and then isolating the fusion protein from the culture fluid and/or bacterial cells. Thus obtained fusion protein may be further purified based on an affinity to a support carrying glutathione, e.g., glutathione sepharose beads, wherein the elution of the fusion protein from the glutathione sepharose beads may be performed by boiling in the presence of a detergent. The detergent may include sodium dodecyl sulfate, CHAPS (3-[(3-cholamide propyl) dimethylammonio]-1-puopane sulfonate), deoxycholic acid, digitonin, n-dodecylmaltoside (1-O-n-dodecyl- β -D-glucopyranosyl (1-4)

α -D-glucopyranoside), NonidetTM P40 (ethylphenolpoly (ethylene glycol ether)n), n-octylglucoside (1-O-n-octyl- β -D-glucopyranoside), sucrose monolaurate, TesitTM (dodecylpoly (ethylene glycol ether)n), TritonTM X-100 (octylphenolpoly (ethylene glycol ether)n), TweenTM 20 (poly (oxyethylene) n-sorbitan-monolaurate), N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and the like [any of 'n' represents an integer number which is more than or equal to 1]. When elution of the fusion protein is carried out, the resin may be boiled at 100°C for 5-10 minutes in the presence of such detergents at a concentration that does not lead any problems to an animal to be administered, preferably 0.1% of sodium dodecylsulfate. Accordingly, a purified fusion protein, which is preferable as a contemplated immunogen, can be obtained.

When a monoclonal antibody is generated using such a fusion protein as an immunogen, a LAR phosphatase subunit may be employed for screening the antibody, however, it is more preferable to perform the screening using the fusion protein as an immunogen in terms of the specificity

The exemplary monoclonal antibody of the present invention may include a monoclonal antibody having a molecular weight of about 150 kDa that is produced from mouse/mouse hybridoma cells. The antibody can be applied as a tool for further elucidation of the mechanisms of an insulin signaling system, for developing useful diagnostic methods of insulin resistance and NIDDM, and for prophylaxis, therapeutics and diagnosis of several kinds of pathological states relating to syndrome X based on insulin resistance. Moreover, the antibody of the present invention may be useful for identification and acquisition of LAR related molecules, for example, modulator, binding protein and the like.

Further aspect of the present invention is to provide a hybridoma cell line producing the above-mentioned monoclonal antibody. Such a hybridoma cell line may include mouse/mouse hybridoma cell line YU1, which was deposited on May 7, 1998, with

National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-1-320, Higashi, Tsukuba, Ibaraki, JAPAN, and assigned Accession No FERM BP-6343

The antibody of the present invention has specific immunoreactivity with LAR protein, and fragments and polypeptides that comprise at least a LAR intracellular domain (the fragment and polypeptide are hereinafter collectively referred to as 'LAR derived molecules'), which was derived from natural sources, or wholly or partially synthesized (such as those chemically synthesized, or recombinantly synthesized).

Another aspect of the present invention is to provide a method for generating an antibody having specificity to a LAR phosphatase subunit, wherein the aforementioned fusion protein comprising a LAR phosphatase domain and another protein or a polypeptide fragment, preferably a GST-LAR phosphatase domain fusion protein, is employed as an immunogen. In this aspect of the present invention, the available another protein or a polypeptide fragment except GST to be a member of the fusion protein, and purification process of the fusion protein are as set forth above.

Further, a fusion protein comprising GST and a LAR phosphatase domain which is a preferable immunogen may be suitably produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours, preferably at 23-25°C for 18 hours; and then isolating the fusion protein from the culture fluid and/or bacterial cells. Thus obtained fusion protein may also be further purified based on an affinity to a support carrying glutathione, e.g., glutathione sepharose beads wherein the elution of the fusion protein from the glutathione sepharose beads may be performed by boiling in the presence of a detergent, as set forth above, and then, for eluting the fusion protein, the resin may be boiled at 100°C for 5-10 minutes in the presence of the detergent at a concentration which does not lead any

problems to an animal to be administered, preferably 0.1% of sodium dodecylsulfate. Accordingly, the purified fusion protein, which is preferable as a contemplated immunogen, can be obtained.

In a method of generating a monoclonal antibody by using such a fusion protein as an immunogen, a LAR phosphatase subunit may be employed for screening the antibody, however, it is more preferable to perform the screening using the fusion protein as an immunogen in terms of the specificity.

The present invention further provides a method of quantitative determination of LAR and/or LAR derived molecules. The method is characterized by comprising the steps of: determining an amount of LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain, which is contained in a test sample using an antibody set forth above. In this method, the antibody set forth above is used preferably in any of immunoblotting, immunoprecipitation and ELISA, for determining the amount of LAR or LAR derived molecules.

Still another aspect of the present invention is to provide a method for quantitative determination of LAR and/or LAR derived molecules comprising the step of: isolating LAR and/or LAR derived molecules from a test sample using the antibody set forth above; and measuring an activity of the isolated LAR and/or LAR derived molecules. In this method, in order to isolate the LAR and/or LAR derived molecules, affinity chromatography and/or immunoprecipitation by using a support that was bound with the aforementioned antibody are suitably utilized. Namely, affinity chromatography using a column or batch wise method, and/or immunoprecipitation may be performed wherein the support which was previously bound with the antibody is contacted with a test sample to allow specific interaction between antigen (LAR/LAR derived molecules) and antibody, then after washing the unbound antibody, the bound LAR/LAR derived molecules may be eluted.

Amended under PCT Art. 34(2)(b)

In yet another aspect of the present invention, a method for producing LAR and/or LAR derived molecules is provided, comprising the step of: isolating LAR and/or LAR derived molecules using the antibody set forth above. Isolation of the targeted molecules in the method for production may be suitably carried out by affinity and/or immunoprecipitation by using a support that was previously bound with the antibody, as in the aforementioned method of quantitative determination of LAR and/or LAR derived molecules

Further aspect contemplated by the present invention is to provide a method for identifying the presence of LAR and/or LAR derived molecules within tissue comprising the step of: performing immunohistological examination using the aforementioned antibody. As the immunohistological examination, for example, *in situ* immunohistological staining with a labelled antibody may be adopted, thus LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain, can be detected.

The present invention is further directed to a specific anti-LAR antibody to thyroid carcinoma cells. The antibodies may be those elicited using a LAR molecule as well as the fragment thereof, e.g., a phosphatase domain, an extracellular domain or the like as an antigen, and may include monoclonal and polyclonal antibodies, peptide antibodies, single chain antibodies, chimeric antibodies, humanized antibodies, CDR-grafted antibodies and the like. Particularly, the aforementioned antibodies to a LAR phosphatase subunit, those having immunoreactivity with thyroid carcinoma cells are provided by the present invention. Herein, "having immunoreactivity with thyroid carcinoma cells" means that almost no immunoreactivity with normal thyroid cells or benign tumor thyroid cells (less than or equal to 10% of the normal cells) is exhibited, whilst higher immunoreactivity to the thyroid carcinoma (more than or equal to 20% of the carcinoma cells) is exhibited.

Amended under PCT Art. 34(2)(b)

Accordingly, it makes possible to diagnose thyroid cancer through utilizing such an antibody, thus a method for histological diagnosis of thyroid carcinoma is also contemplated by the present invention. The diagnostic method is characterized by comprising the steps of: taking a thyroid tissue sample (specimen) from a subject suspected as suffering from thyroid cancer, and conducting diagnosis of thyroid cancer through evaluating immunoreactivity between the antibody set forth above and the tissue specimen. In this instance, the thyroid tissue specimens may be any of the specimens such as those taken by fine needle aspiration from a subject, or those prepared by excision and extirpation of a part of the thyroid. The diagnostic method where the specimens taken by fine needle aspiration are employed is more preferable in respect of lower invasiveness to the subject. This is an important advantage provided by the present invention taking into account of the nature of the diagnostic method of thyroid cancer based on the histological observation of the tissue, where highly invasive incision procedure has been obliged to practice. Additionally, also in the immunohistochemical diagnostic method utilizing the tissue section, the present invention is more useful because more prominent reliability can be achieved than in the conventional method.

In the above-described diagnostic method, the specimens taken by fine needle aspiration may be evaluated for their immunoreactivity by common *in vitro* immunoassays e.g., immunoblotting, immunoprecipitation, ELISA or the like, using the antibody of the present invention. In contrast, when tissue sections are used as specimens, conventional immunohistochemical staining techniques can be utilized to determine the immunoreactivity based on immune responses.

Moreover, the present invention provides a composition for histological diagnosis of thyroid carcinoma comprising the aforementioned antibody. Markedly reliable diagnostic method of thyroid cancer as set forth above can be performed using

this composition. The composition may include excipient, carrier, buffer, agent for stabilizing the antibody and the like ad libitum, in addition to the antibody

Consequently, in accordance with the present invention, specific and high expression of LAR in thyroid carcinoma cell was revealed. Furthermore, it was also verified that monoclonal antibody of the present invention is useful for diagnosis of thyroid cancer as illustrated in Examples. Additionally, the monoclonal antibody of the present invention was proven to be useful for the diagnosis of thyroid carcinoma where tissue sections are employed (see, Example 5, 6), and for the diagnosis where homogenized tissue is employed (see, Example 7). From these results, the person skilled in this art will comprehend that the monoclonal antibodies of the present invention are useful for several kinds of cytological or histological diagnoses or biopsy. Moreover, besides the present monoclonal antibodies, monoclonal antibodies, polyclonal antibodies, and/or peptide antibodies that can recognize a LAR extracellular domain may also be utilized in such processes. Again in such cases, the processes may be nevertheless practiced similarly to those where the present monoclonal antibodies are employed, however, effects resulting from release of the extracellular domain would be preferably considered.

It was revealed by the present invention that the antibodies to LAR can be utilized for diagnosis and therapy of diseases related to thyroid carcinoma. An amount of LAR or a fragment thereof may be determined using such an antibody on the basis of immunological binding between them. Specifically, the method of determining an amount of LAR or a fragment thereof may include for example, a sandwich method wherein sandwich complex is detected that was produced by an immunoreaction of LAR or a fragment thereof with an antibody bound to an insoluble support and labelled antibody; and a method wherein an amount of LAR or a fragment thereof in a sample is determined utilizing a competition method by competitively immunoreacting LAR or a fragment

thereof and labelled LAR with the antibody, and then determining an amount of LAR or a fragment thereof from the amount of the labelled antigen that bound to the antibody.

When an amount of LAR or a fragment thereof is determined by the sandwich method, a two steps method wherein an immunoreaction of an immobilized antibody with LAR or a fragment thereof is allowed first, then unreacted substances are completely removed by washing, a labelled antibody is added thereto thus a labelled antibody-LAR or a fragment thereof complex is formed; or a one step method wherein an immobilized antibody, a labelled antibody, and LAR or a fragment thereof are simultaneously mixed.

Insoluble support used for such determination may include for example, synthetic resin such as polystyrene, polyethylene, polypropylene, polychlorinated vinyl, polyester, polyacrylate ester, nylon, polyacetal, fluorine contained resin and the like, polysaccharides such as cellulose, agarose and the like; glass; and metal etc. The insoluble support may be in several forms for example, tray-like, spherical, fibrous, cylindrical, discal, vessel-like, cell-like, tubular and so on. The support with the absorbed antibody is stored in a cold place, in the presence of an antiseptic agent such as sodium azide.

For immobilization of an antibody, a known chemical binding method or a physical absorption method may be adopted. The chemical binding method may include for example, glutaraldehyde-utilizing method, maleimide method wherein N-succinimidyl-4-(N-maleimidemethyl) cyclohexane-1-carboxylate, N-succinimidyl-2-maleimideacetate or the like may be used, carbodiimide method wherein 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride may be used. In addition, maleimidebenzoyl-N-hydroxysuccinimide ester method, N-succinimidyl-3-(2-pyridylthio) propionic acid method, bisdiazotized benzidine method, dipalmityllysine method may be included. Alternatively, a complex which was previously formed by a reaction of a detection test material with an antibody of which epitope is in a different kind, may also be captured after the third antibody to said antibody is immobilized according to the method as

mentioned above.

The material to be used for labelling the antibody may be enzyme, fluorescent material, luminescence material, radioactive material, metal chelate or the like. An enzyme may include for example, peroxidase, alkaline phosphatase, β -D-galactosidase, malate dehydrogenase, staphylococcus nuclease, delta-5-steroid isomerase, α -glycerolphosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, asparaginase, glucose oxidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholine esterase, and the like, and fluorescent material may include for example, fluorescein isothiocyanate, phycobilin protein, rhodamine, phycoerythrin, phycocyanin, orthophthalic aldehyde and the like; luminescence material may include isoluminol, lucigenin, luminol, aromatic acridiniumester, imidazole, acridinium salt and modified ester thereof, luciferin, luciferase, aequorin and the like; and radioactive material may include ^{125}I , ^{127}I , ^{131}I , ^{14}C , ^3H , ^{32}P , ^{35}S and the like, but not limited thereto as long as the material can be used in immunological determination methods. Further, low molecular weight hapten such as biotin, dinitrophenyl, pyridoxal or fluorescamine may be conjugated to the antibody. Preferably horseradish peroxidase may be used as a labelling enzyme. This enzyme can react with a lot of substrates, while being readily conjugated to the antibody by a periodic acid method.

When an enzyme is used as a labelling material, a substrate for measuring its activity, and a color-developing agent are employed. When peroxidase is used as an enzyme, H_2O_2 may be used as a substrate solution, and 2,2'-azino-di-[3-ethylbenzthiazolin sulfonate] ammonium (ABTS), 5-aminosalicylic acid, orthophenylenediamine, 4-aminoantipyrine, 3,3',5,5'-tetramethylbenzidine or the like may be used as a color-developing agent; when alkaline phosphatase is employed as an enzyme, the substrate may be orthophenylphosphate, paranitrophenylphosphate or the like; alternatively, when β -D-galactosidase is used as an enzyme, the substrate may be

Amended under PCT Art. 34(2)(b)

fluorescein-di-(β -D-galactopyranoside), 4-methyl-umbelliferyl-D-galactopyranoside, or the like.

The present invention further contemplates a kit, which comprises the above-described monoclonal antibody or polyclonal antibody, and reagents.

As a crosslinking agent, N,N'-orthophenylenedimaleimide, 4-(N-maleimidemethyl) cyclohexanoyl N-succinimide ester, 6-maleimidehexanoyl N-succinimide ester, 4,4'-dithiopyridine, orthophenylenedimaleimide, 4-(N-maleimidemethyl) cyclohexanoyl N-succinimide ester, 6-maleimidehexanoyl N-succinimide ester, 4,4'-dithiopyridine, or other known crosslinking agents can be utilized. The reaction of such a crosslinking agent with the enzyme and the antibody may be proceeded in accordance with known methods depending upon the properties of the crosslinking agent that was employed.

Additionally, the antibodies to be used may be any fragments of these antibodies for example, Fab', Fab, F(ab')₂ depending on conditions. Furthermore, an enzymatically labelled antibody can be obtained by a similar process in either case of polyclonal antibody or monoclonal antibody, whichever. When the enzymatically labelled antibody that was obtained by using the aforementioned crosslinking agent is purified by any known methods, more sensitive immunological determination system can be achieved. The enzymatically labelled antibody that was purified in such a manner may be mixed with a stabilizer such as thimerosal, glycerol or the like, alternatively, may be lyophilized, and then stored in a cold and dark place.

The present invention further provides a DDS (Drug Delivery System) formulation that was targeted to thyroid carcinoma cells using the above-described antibody having specific immunoreactivity to thyroid carcinoma cells.

It have been elucidated that several genes are involved in thyroid carcinoma. Mutations in tyrosine kinase domain of Ret or TRK gene were found in some of the

Amended under PCT Art. 34(2)(b)

patients suffering from papillary carcinoma (Fusco, A. *et al.*, *Nature*, **328**, 170-2, 1987). Moreover, mutation in Ret gene was observed in 3-30% of the papillary carcinoma patients without any history of a radiation exposure in the past (Santoro, M. *et al.*, *J. Clin. Invest.*, **89**, 1517-22, 1992; Bongdrzone, I. *et al.*, *J. Clin. Endocrinol. Metab.*, **81**, 2006-9, 1996; Zou, M. *et al.*, *Cancer*, **73**, 176-80, 1994), whilst higher incidence of 60-80% of the Ret mutation was observed in papillary carcinoma diagnosed, for children with experiences of radiation exposure on the disaster at Chernobyl nuclear power plant, or the patients who have case histories of radiation exposure in their childhood (Fugazzola, L. *et al.*, *Cancer Res.*, **55**, 5617-20, 1995; Klugbauer, S. *et al.*, *Oncogene*, **11**, 2459-67, 1995; Nikiforov, Y. E. *et al.*, *Cancer Res.*, **57**, 1690-4, 1997; Bounacer, A. *et al.*, *Oncogene*, **15**, 1263-73, 1997), and frequency of TRK gene mutation is significantly low (Bongdrzone, I. *et al.*, *J. Clin. Endocrinol. Metab.*, **81**, 2006-9, 1996). Point mutation of Ras gene is frequently observed in goiter and thyroid follicular carcinoma. The basis of this fact is conceived as Ras gene point mutation in an early stage of tumor development (Fagin, J. A., *Molecular pathogenesis*. In: Braverman LE, Utiger RD, eds. *Werner and Ingbar's, the thyroid: a fundamental and clinical text*. 7th ed. Philadelphia: Lippincott-Raven, 909-16, 1996; Challeton, C. *et al.*, *Oncogene*, **11**, 601-3, 1995). The mutation of genes encoding TSH and stimulatory G protein is reported in some cases of thyroid follicular carcinoma (Challeton, C. *et al.*, *Oncogene*, **11**, 601-3, 1995; Russo, D. *et al.*, *Oncogene*, **11**, 1907- 11, 1995). Further, it was also reported that mutation of tumor suppressor gene p53 is rare in differentiated thyroid carcinoma, however, it is frequently found in undifferentiated carcinoma (Fagin, J. A. *et al.*, *J. Clin. Invest.*, **91**, 179-84, 1993; Ito, T. *et al.*, *Cancer Res.*, **52**, 1369-71, 1992).

According to such known information, a nucleic with the object of therapy or diagnosis of thyroid cancer can be included in a DDS formulation targeted by an antibody to LAR.

Amended under PCT Art. 34(2)(b)

Furthermore, it is also known that proliferation of thyroid carcinoma is regulated by thyroid stimulating hormone (TSH), and that suppression of TSH secretion by administering a thyroid hormone drug may improve recurrence, survival rate or the like of thyroid tumor. Accordingly, a protein, a nucleic acid or a compound that may inhibit TSH stimulation can be also included in the DDS formulation.

On the other hand, the present DDS formulation, which is characterized by targeting to thyroid carcinoma cells using the aforementioned antibody having specific immunoreactivity with thyroid carcinoma cells, may comprise one or more materials which are selected from a group consisting of a nucleic acid, iodine, radioactive iodine, technetium and a protein, accordingly, through including such materials to the formulation, higher targeting ability to thyroid carcinoma is allowed, which can be utilized for therapy or diagnosis of thyroid cancer.

“Nucleic acid” herein refers to for example, a nucleic acid encoding a protein that can be expressed in a host cell, an antisense nucleic acid derived from cells, a nucleic acid of a decoy having a sequence of a gene encoding a binding protein of a cell-derived transcription factor or a sequence of a binding site of a transcription factor, or a similar sequence thereto.

“Antisense nucleic acid” represents a nucleic acid or a nucleic acid sequence that binds specifically to a nucleic acid being able to be expressed in future, at any stage of the gene expression, i.e., replication, transcription, translation or the like, thus inhibits expression of the nucleic acid which can be otherwise expressed in future. Antisense nucleic acid also includes an anti-gene nucleic acid resulting from a triple strand. A nucleic acid encoding a decoy represents a nucleic acid having a sequence of a nucleic acid encoding a binding protein of a cell-derived transcription factor or a sequence of a binding site of a transcription factor, or a similar sequence thereto, thus through introducing the nucleic acid into a cell as a decoy, binding of a transcription factor to its binding site can be

inhibited, which may lead to suppression of an action of the transcription factor, finally suppression of a group of genes which was going to be activated may be possibly resulted. "Ribozyme" herein means a nucleic acid that can cut mRNA of a specified protein, then inhibits translation of the specified protein. A ribozyme can be designed from a gene sequence encoding the specified protein, which may include herein irrespective of type of the ribozyme, for example, a hammer head type ribozyme, a hairpin ribozyme, a delta type ribozyme and the like, as long as it can cut mRNA of a specified protein, thus leading to inhibition of translation of the specified protein. Suicide gene herein refers to a gene that leads a cell to death consequently, which may include programmed cell death inducing gene, apoptosis inducing gene, necrosis inducing gene and the like.

These nucleic acids can be selected by a person skilled in this art, and through including these nucleic acids into the DDS formulation, specific death of thyroid carcinoma cells can be achieved.

By adding radioactive iodine (^{131}I) to the formulation, normal thyroid cells are destroyed, thus metastasis of carcinoma can be readily detected in systemic radioactive iodine scintillation test. Further, by measuring blood thyroglobulin value, remained carcinoma after operation, or recurrence can be identified. In addition, radioactive iodine therapy makes it possible to prevent from recurrence by destructing latent carcinoma, and systemic radioactive iodine scintillation test can be realized through using of a lot of radioactive iodine for therapy. This test is highly sensitive for finding carcinoma remained. Therefore, by using the antibody of the present invention, or the iodine labelled or radiolabelled antibody, usefulness in diagnosis or therapy may be further improved.

Moreover, the protein may include antibodies, TSH (Thyroid Stimulating Hormone), thyroid hormone and the like.

The above-mentioned DDS formulation comprising the materials as set forth above is useful as a pharmaceutical composition for diagnosis of thyroid cancer, or for

pharmaceutical composition for therapy of thyroid cancer

Furthermore, a pharmaceutical composition of the present invention allows for practicing an effective chemotherapy accompanied by less side effects, through concentrating a drug to the focal portion utilizing an ability of this antibody to bind to thyroid carcinoma cells based on specific immunoreactivity, when a therapeutic treatment of thyroid carcinoma using a chemotherapeutic agent is intended

Effective chemotherapeutic agent of thyroid carcinoma may include anticancer agent such as cyclophosphamide, adriamycin, streptozotocin, 5-fluorouracil, dacarbazine, vincristine and the like.

An administration process of the above-described pharmaceutical composition may be either of which by systemic administration or topical administration. Systemic administration may include oral administration, intravenous administration, subcutaneous and intramuscular injection, rectal administration, and the like, and topical administration may be preferably performed by direct administration into thyroid tissue, or administration into a vein that is connecting to thyroid tissue.

Dosages of the pharmaceutical composition of the present invention may depend upon the known effective blood concentration level of a drug, which should be determined ad libitum by the skilled person in this art. Additionally, in case of a liposome formulation is prepared, it is important to use the antibody at a dose that does not hamper the liposome formation.

When particularly administered to human, the antibody to be included in the DDS formulation may be preferably the above-described humanized antibody, chimeric antibody or the like without any immunogenicity to human, or with less immunogenicity to the at most. When a mouse monoclonal antibody is administered to a human body, risks of occurrence of various side effects are prospected, because such an antibody is a heterogeneous protein to human. Accordingly, although using a human monoclonal

antibody is desirable. fusion efficiencies may be inferior, and obtaining a hybridoma that is stably producing an antibody could be difficult. However, the technologies have been progressing currently, thus generation of human monoclonal antibodies or chimeric antibodies have been enabled.

Chimeric antibody may be a chimeric molecule comprising a mouse antibody and a human antibody. Producing an antibody by immunizing a human with an arbitrary antigen is ethically impossible. Therefore, a mouse is immunized first, then a gene portion of an antibody valuable region (V region) that binds to the antigen of the resulted mouse monoclonal antibody is excised therefrom, and this gene portion is linked to a gene encoding an antibody constant region (C region) from human myeloma, to produce a chimeric gene. When thus prepared chimeric gene is expressed in a host cell, a human-mouse monoclonal antibody can be produced. Because chimeric antibodies are less immunogenic to human, it can be utilized as monoclonal antibodies to be administered to a human body for therapy or diagnostic imaging. Known relevant arts of chimeric antibodies may include Japanese provisional publication No. Hei 05-304989, Japanese provisional publication No. Hei 04-330295, PCT publication No. WO9106649, Japanese provisional publication No. Sho 63-036786, Japanese publication No. Hei 06-98021 and the like.

More recently, however, humanized antibodies were discovered, which are reported to be more useful than chimeric antibodies. Humanized antibody is an antibody of which entire molecule was humanized except for CDR (Complementarity Determining Region) of the antibody molecule, by grafting only CDR encoding gene of the antibody molecule to a gene encoding humanized antibody (CDR). The humanized antibodies have less mouse-derived antibody portion than human-mouse chimeric antibodies, thus they are reported to be less antigenic and safer. In Japan, clinical tests on humanized antibodies to adult T-cell leukemia have been presently performed. With respect to procedures for

producing humanized antibodies and the related arts, see, for example, PCT publication Nos WO9222653, WO9845332, WO9404679, WO9837200 and WO9404679 of Genentech, USA, and PCT publication Nos. WO9429451, WO9429351, WO9413805, WO9306231, WO9201059, WO9116927, WO9116928, WO9109967, WO8901974, WO8901783 of Celltech, United Kingdom and the like.

Method for producing human monoclonal antibodies may include in addition to a cell fusion method, a transformation method with Epstein-Barr virus (EBV), and another fusion method of thus transformed cells and parent cells, a method of producing a chimeric antibody or a humanized antibody utilizing genetic engineering, and the like. A chimeric antibody refers to an antibody prepared by linking immunoglobulin gene fragments of heterologous animals, and a humanized antibody refers to an antibody prepared by modifying a heterologous antibody to human, such as a mouse antibody, wherein a primary structure except for CDR (Complementarity Determining Region) in H chain and L chain is substituted for corresponding primary structure of a human antibody. As parent cells for producing human monoclonal antibody, SHM-D 33 strain (ATCC CRL 1668) or RF-S1 strain may be employed, which is human/mouse heteromyeloma, so that high fusion efficiency that is equal to mouse parent cells can be resulted. Hybridoma obtained using such parent cells can be cloned without feeder cells, and can produce IgG type antibodies in a relatively stable manner, on a large scale. For culturing the parent cells, ERDF medium containing 15% FCS may be employed, and another procedures may be similarly carried out to the case of culture of mouse parent cells. In addition, it is preferable to use sufficiently sensitized human lymphocytes with the antigen, which are collected from peripheral blood, for producing IgG type human monoclonal antibodies. When obtaining such sufficiently sensitized lymphocytes with an antigen is difficult, *in vitro* sensitization with the antigen may also be performed.

Using the methods set forth above, the present antibody can be humanized, and

Amended under PCT Art. 34(2)(b)

thus it is markedly useful for administration to a human body.

In addition, usefulness may be enhanced as a diagnostic/therapeutic drug, through radiolabelling such an antibody with iodine, or including radiolabelled iodine into a pharmaceutical composition that was targeted with the antibody.

When papillary carcinoma or follicular carcinoma invades into surrounding tissue or metastasizes to a distal portion (especially to lung and bone) or lymph node through blood circulation or lymphatically, a common therapeutic strategy for destroying the carcinoma cells has been administration of radiolabelled (^{131}I) iodine. Normal thyroid cells incorporate iodine from the blood and concentrate it. This process is stimulated by TSH (Thyroid Stimulating Hormone) that is secreted from pituitary gland. Iodine is thereafter used to produce thyroid hormone (thyroxine T₄). As set forth above, thyroid carcinoma or metastatic area of carcinoma normally incorporates only slight amount of iodine (or radioactive iodine). However, when carcinoma is under influences of abundant TSH, a part of thyroid carcinoma or metastatic one becomes liable to incorporate a significant amount of iodine upon stimulation. Consequently, a large amount of radiation is allowed to be directly exposed to carcinoma without injuring the surrounding tissue. When intact thyroid is present in a body with producing a normal level of thyroid hormone, TSH level that is produced may remain relatively low, however, upon decrease of thyroid hormone level due to removal of whole thyroid or its destruction, pituitary gland rapidly accelerates TSH secretion. The TSH stimulates thyroid carcinoma, leading to incorporation of radioactive iodine. When radioactive iodine therapy is performed for progressed thyroid carcinoma, whole thyroid must be removed almost completely by an operation, and the residual tissue is required to be destroyed using radioactive iodine. Once this procedure is carried out, patients having carcinoma cells remained in the neck area or those having metastatic carcinoma to a distal place are subjected to scanning when their TSH level is high enough, using a test amount of radioactive iodine (normally 2-10

Amended under PCT Art. 34(2)(b)

mCi). If substantial amount of radioactive iodine was proved to assemble to a region of thyroid carcinoma, yet more therapeutic amount of radioactive iodine (normally 100-200 mCi: 3700-7400 MBq) is administered in an attempt of destruction of the carcinoma cells. Because radioactive iodine is safe and effective also to the patients having more invasive thyroid carcinoma, many physicians have learned to use radioactive iodine routinely for less invasive papillary carcinoma or follicular carcinoma.

Therefore, by labelling the antibody that binds to LAR using iodine, or by including radioactive iodine into a pharmaceutical composition targeted with the antibody, specificity to thyroid carcinoma cells can be further enhanced, thus therapeutic or diagnostic utilization may be enabled.

Accordingly, an anti-LAR antibody that specifically recognizes thyroid carcinoma cells is also useful in a Drug Delivery System (DDS). Drug Delivery System (Mitsuru Hashida, *Drug Delivery System*, New Challenges to Manufacturing Drugs and Therapy, Kagaku Doujin, (1995)) is a novel technique related to drug administration aiming at: contriving administration routes or forms of drugs; delivering the drugs selectively to targeted sites by controlling pharmacokinetics of the drugs in a body; achieving the optimal therapeutic effects as a result; and minimizing the adverse effects exerted by the drugs. Although various DDS formulations have been developed heretofore, liposome formulations (Hiroshi Terada, Tetsuro Yoshimura *eds.*, *Experiment Manual of Liposome in Life Science*, Springer-Verlag, Tokyo, (1992)) are among all highlighted in supplementation of a deficient enzyme, administration of carcinostatic agent and antibiotics, as well as in gene therapy.

Liposome is a closed small vesicle composed of a lipid bilayer of which basis is phospholipid that constructs a biomembrane, which is known to be safe with a superior function as a drug carrier, because it can capsule various drugs irrespective of their solubility whether the drugs may be lipid soluble or water soluble, according to their

Amended under PCT Art. 34(2)(b)

composition comprising a lipid membrane and an aqueous layered part.

In addition, it is well known that a targeting ability can be imparted to a liposome through binding an antibody, peptide or the like on the surface of the liposome (Kazuo Maruyama, Tomoko Takizawa, Motoharu Iwatsuru *et al.*, *Biochimica et Biophysica Acta* **1234**, 74 (1995; Jlbao Zhao, Shunsaku Kimura, Yukio Imanishi, *Biochimica et Biophysica Acta* **1283**, 37 (1996)). Accordingly, anti-LAR antibodies can be used for the purpose of improving specificity to thyroid carcinoma cells of various liposome formulations. Further, characteristic features of the liposomes are their abilities to produce a variety of carriers (vectors) of which properties are distinct by alteration of a kind of the lipid, or modifying with polyethylene glycol: for example, temperature sensitive liposomes (Sakae Unezaki, Kazuo Maruyama, Motoharu Iwatsuru *et al.*, *Pharmaceutical Research* **11**, 1180 (1994)), liposomes with stability in blood (Kazuo Maruyama, Tsutomu Yuda, Motoharu Iwatsuru *et al.*, *Biochimica et Biophysica Acta* **1128**, 44 (1992)), cationic liposomes as plasmid introducing vector (Xlang Gao, Daniel Jaffurs, Leaf Huang *et al.*; *Biochemical and Biophysical Research Communications* **200**, 1201 (1994)), and the like can be prepared.

However, liposomes are usually incorporated into cells by an endocytotic pathway followed by incorporation into early endosomes proximal to the cell membrane. Then, the liposomes are delivered to late endosomes in a deeper part of the cell, and finally transferred to lysosomes. The liposomes that were transferred to lysosomes are degraded by actions of hydrolytic enzymes, and the drugs capsulated in the liposomes are simultaneously metabolized, therefore, there exists a problem that the accessible rate of the drugs that are kept unchanged into the cytoplasm may be extremely low.

Currently, a method for introducing drugs and the like directly into the cytoplasm without any injury against a cell membrane that is a barrier of a cell has been studied. For example, when liposomes gain an ability to fuse with a membrane, drugs introduced thereinto would be able to be delivered directly into the cytosol without transfer via lysosomes. Methods for fusion of the liposome with a cell have been studied heretofore.

which may include. pH sensitive liposomes (Kenji Kono, Ken-ichi Zenitani, Toru Takabishi, *Biochimica et Biophysica Acta* **1193**, 1(1994)), and reconstituted liposomes that are liposomes incorporated with an envelope protein of virus thereinto (Sangeeta Bagai, Debi P Sarkar, *The Journal of Biological Chemistry* **269**, 1966(1994)).

Recently, a fusiogenic liposome (HVJ-liposome) was reported, which is a liposome with an imparted ability of Sendai virus (Hemagglutinating Virus of Japan) to fuse with a membrane (Yoshio Okada, *Current topics in Membranes and Transport* **32**, 297 (1988)). Sendai virus (HVJ) is a pioneering virus for genetics in which animal cells were employed, based on observation of an intercellular fusion event (Y. Maeda, J. Kim, Y. Okada *et al.*, *Experimental Cell Research* **108**, 108 (1977)). Furthermore, HVJ can also fuse with liposomes (Mahito Nakanishi, Tsuyoshi Uchida, Yoshio Okada *et al.*, *Experimental Cell Research* **159**, 399 (1985)), and the fusion body (HVJ-liposome) can in turn fuse with a cell membrane. Namely, HVJ-liposome that was prepared by a direct reaction between a liposome and HVJ is a so-called hybrid vector, carrying a cavity inside which is derived from the liposome, and an outside spike structure identical to that of a viral envelope. HVJ-liposomes can introduce any substances as long as they can be capsulated into liposomes, such as proteins, chemical substances, genes and the like, into cells at high efficiencies that are equivalent to Sendai virus (Tetsuhiko Nakagawa, Hiriuyuki Mizuguchi, Tadanori Mayumi, *Drug Delivery System* **11**, 411 (1996)). Additionally, an improved type of HVJ-liposome was proposed wherein introducing efficiencies may be enhanced by co-introduction with DNA and a nuclear protein HMG-1 (Non-histone chromosomal protein, High Mobility Group-1) having a DNA binding ability (Yasufumi Kaneda *et al.*, *J.Molec. Medicine* **73**, 289 (1995)).

Another example of a membrane-fused liposome that can be used is a liposome formulation in which VSV (Vesicular Stomatitis Virus; Yoshiyuki Nagai, Akira Ishihama *ed.*, *Protocols for Experiments of Virus*, Medical View (1995)) is utilized (*J. Virol*, **72**(7),

6159-63, 1998, *Exp. Cell. Res.*, **200**(2), 333-8, 1992, *Proc. Natl. Acad. Sci. USA*, **87**(7), 2448-51, 1990, and *Biochim. Biophys. Acta*, **987**(1), 15-20, (1989)). VSV is a single strand RNA (-) virus belonging to genus *Vesiculovirus* in family *Rhabdovirus*, having G protein that is an envelope protein on a membrane surface (Akihiko Kawai, *Journal of Virology* **24**, 826 (1977)) Infection mechanisms of VSV to cells may proceed via an endocytotic pathway similarly to liposomes. However, to be distinct from liposomes, because VSV has a characteristic to fuse with an endosome membrane, VSV introduces its own gene into cytoplasm without degradation by hydrolytic enzymes contained in lysosome. So far, it has been noted that VSV has an ability to fuse with a membrane, and that any hemolytic action is not exhibited against human erythrocyte by VSV (Carole A. Bailey, Douglas K. Miller, John Lenard, *Virology* **133**, 111(1984)). Further, because VSV utilizes ubiquitously existing phosphatidylserine in lots of tissue cells as a receptor, wide variety of hosts may be allowed (Michael J. Clague, Christian Schoch, Robert Blumenthal, *Biochemistry* **29**, 1303 (1990)), and propagation of this virus quickly proceeds, thus characteristics of VSV may be that the virus can be readily collected at a large amount. On the other hand, it is reported that VSV and liposome may result in fusion (Satoshi Yamada, Shunichi Ohnishi, *Biochemistry* **25**, 3703 (1986))

As explained in detail, anti-LAR antibodies can be utilized for the purpose of enhancement of targeting abilities of any kinds of liposome formulations, including membrane-fused liposomes, pH sensitive liposomes, reconstitution liposomes, cationic liposomes and the like, or modified types thereof.

Besides, substantive reports on methods for enhancing targeting abilities using monoclonal antibodies and their usefulness have been found (*Hum. Antibodies*, **9**(1), 61-5, 1999; *J. Clin. Pharm. Ther.*, **22**(1), 7-19, 1997; *J. Int. Med. Res.*, **25**(1), 14-23, 1997; *Proc. Natl. Acad. Sci. USA*, **93** (24), 14164-9, 1996, *Hepatology*, **22**(5), 1482-7, 1995; *Hepatology*, **22**(5), 1527-37, 1995, *Proc. Natl. Acad. Sci. USA*, **92**(15), 6986-90, 1995;

Immunomethods, 4(3), 259-72, 1994, *J. Drug Target*, 2(4), 323-31, 1994, *Cancer Res.*, 57(10), 1922-8, 1997; *Crit. Rev. Biotechnol.*, 17(2), 149-69, 1997, *Methods Find Exp. Clin. Pharmacol.*, 16(7), 505-12, 1994; *Trends Biotechnol.*, 12(6), 234-9, 1994, and *Bioconjug. Chem.*, 4(1), 94-102, 1993), thus monoclonal antibodies to LAR can be used in therapeutic treatment of thyroid carcinoma according to the above-described literatures or known techniques.

Further in addition, anti-LAR antibodies of the present invention can be utilized with contemplation in targeting to thyroid carcinoma, for gene therapy with viral vectors, or for DDS formulations wherein polyacid-glycolic acid microsphere, lipid microsphere, polyethylene glycol-modified enzyme or the like is used.

In still another embodiment of the present invention, high expression of LAR in thyroid carcinoma cells can bring comprehension that high rate of transcription from a LAR molecule-encoding nucleic acid sequence to mRNA followed by translation is conducted in those cells. Accordingly, persons skilled in this art can readily diagnose carcinoma through measuring an expression level of LAR mRNA by using probes for the mRNA.

Furthermore, the present invention can contribute substantially to molecular biological studies on transcription factors, promoters, enhancers, or the like that may accelerate the transcription of LAR in thyroid carcinoma cells

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 is a schematic drawing depicting a subunit structure of LAR (a); and a schematic drawing illustrating the mutated LAR phosphatase domain structures inside the membrane (b) prepared as demonstrated in Examples.

Figure 2 represents immunoblots illustrating time dependent tyrosine phosphorylation induced by insulin stimulation in COS cells that were cotransfected

Amended under PCT Art. 34(2)(b)

with LAR/CS and wild type insulin receptor.

Figure 3 represents immunoblots illustrating phosphorylation-dephosphorylation in COS cells that were cotransfected with wild type or mutants of LAR, and wild type insulin receptor.

Figure 4 represents an immunoblot illustrating dephosphorylation of a β -chain of insulin receptor by wild type or mutants of LAR.

Figure 5 represents an immunoblot illustrating tyrosine phosphorylation of insulin receptor and LAR in COS cells that were cotransfected with wild type or mutant of insulin receptor, and LAR/CS.

Figure 6 represents SDS-polyacrylamide gel, showing a molecular weight of the antibody YU1 of the present invention.

Figure 7 represents immunoblots showing immunospecificity of the antibody YU1 of the present invention.

Figure 8 represents immunoblots showing tyrosine phosphorylation of LAR by tyrosine kinase of insulin receptor.

Figure 9 is a schematic drawing depicting a signal transduction cascade of insulin that is controlled by phosphorylation-dephosphorylation in which insulin receptor and LAR participate.

Figure 10 represents immunoblots of thyroid normal and carcinoma tissues with the antibody YU1 of the present invention, demonstrating the specific immunoreactivity with human thyroid carcinoma tissue.

Figures 11-13 represent photos showing positive immunostaining of thyroid carcinoma cells, but not in normal follicular cells using the antibody YU1 of the present invention.

Figure 14 represents results of immunoblotting demonstrating tissue distribution of LAR in mouse using the antibody YU1 of the present invention.

BEST EMBODIMENT FOR CARRYING OUT THE INVENTION

Experimental Example 1 Tyrosine phosphorylation of insulin receptors by LAR mutants and studies on association between LAR and insulin receptors

First, in order to elucidate signal transduction controlling mechanisms of insulin by LAR, analysis was performed with a strategy in which mutated LAR is used that was prepared by substitution of cysteine with serine, which exists in a catalytic center of PTP domain of LAR.

A) Expression vector of LAR and insulin receptors

Three kinds of LAR expression vectors were used, i.e., (a) LAR WT: human wild type LAR (SEQ ID NO: 3); (b) LAR C/S: mutated LAR, having substitution of cysteine in a catalytic center of LAR-PTP domain 1 (amino acid residue position 1552 of SEQ ID NO: 3) for serine by substituting nucleotide G, position 4983 of SEQ ID NO: 3, with C; and (c) LAR DC/S: further mutated one in addition to LAR C/S, with substitution of cysteine in LAR-PTP domain 2 (amino acid residue position 1813 of SEQ ID NO: 3) for serine by substituting nucleotide G with C, position 5856 of SEQ ID NO: 3 (see, Fig. 1 (b)), each of which was incorporated into pMT expression vector (see, Streuli M. *et al.*, *EMBO J.*, **11**, 897-907, 1992; and Streuli M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990).

Meanwhile, insulin receptor expression vectors used were: (a) IR WT: wild type; and (b) IR K1018M: mutated insulin receptor having substitution of lysine of the position 1018 of ATP binding site of wild type insulin receptor, with methionine resulting in deficiency of tyrosine kinase activity, each of which cDNA was incorporated downstream of SR α promoter (see, Kanai F. *et al.*, *Biochemical and Biophysical Research Communications*, **195**, 762-768, 1993)

B) Transfection into COS-7 cells

COS-7 cells were seeded into RPMI 1640 medium (Nissui Pharmaceutical Co.,

LTD) supplemented with 10% fetal calf serum at 1.0×10^6 cells/8 mL/90 ϕ dish, then after 16 hours incubation, expression vectors of LAR C/S and IR WT were cotransfected into COS-7 cells using DEAE-dextran method. The LAR C/S employed was a vector that was revealed to include complete deficiency in tyrosine phosphatase activities *in vitro* (Streuli M. *et al.*, *EMBO J.*, **9**, 2399-2407, 1990) according to mutation as mentioned above in paragraph A, (b).

Cotransfection was performed according to the following procedure. Initially, 40 μ l of 10 mM chloroquine was added to 4 ml of RPMI 1640 medium (10.2 g/L of RPMI 1640 (Nissui Pharmaceutical Co., LTD.) containing 0.3 g of glutamine and 0.1 g of kanamycin, pH 7.4 that was adjusted with 10% NaHCO_3).

To 2 ml of this solution, 5 μ g of LAR expression vector and 1 μ g of IR expression vector were added, on the other hand, 16 μ l of 100 mg/ml DEAE-dextran was added to 2 ml of the remaining solution. Then, both solutions were mixed thoroughly with stirring. Thus prepared 3.75 ml of solution of expression vector was plated at 1.0×10^6 cells/8 ml/dish, and was added to COS-7 cells that had been precultured for 16 hours at 37°C, in a 5% CO_2 incubator. Following 4 hours culture under the similar conditions to the preculture, the cells were treated with 10% DMSO solution for 2 minutes, then washed with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$, 1.4 mM KH_2PO_4), thereafter, 8 ml of RPMI 1640 containing 10% FCS was added thereto, and cultured for 48 hours at 37°C within an incubator that was adjusted to 5% CO_2 .

C) Insulin stimulation and preparation of cell lysate

COS-7 cells after completing transfection were incubated for 16 hours in serum free RPMI 1640 culture medium, followed by stimulation with 10^{-7} M insulin (Seikagaku Corporation) for determined periods, i.e., 0, 1, 5, 15 and 30 minutes. Stimulation for 0 minute was conducted by standing on ice without incubating at 37°C, although insulin was added similarly. After each of the time elapsed from the beginning of insulin stimulation,

culture fluid was entirely aspirated from the cells, and 5 ml of PBS w/Inh. (PBS containing tyrosine phosphatase inhibitors: 1 mM sodium vanadate, 5 mM sodium fluoride, 5 mM sodium pyrophosphate, 5 mM EDTA-2Na, 137 mM NaCl, 2.7 mM KCl, 4.3 mM $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$, 1.4 mM KH_2PO_4) was immediately added.

Following washes of the whole cells with PBS w/Inh., the fluid was removed by aspiration, and 1 ml of lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM iodoacetamide, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.4 mM sodium vanadate, 0.1 mM oxidized phenylarsine, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride) was added to the cells, which were thereafter collected with a cell scraper. The cell suspension was transferred to a 1.5 ml tube, and then incubated at 4°C for 30 minutes to result in complete lysis of the cells. Supernatant, which was obtained by centrifuge of the fluid at 12,000 rpm, 4°C for 10 minutes following incubation was employed as a cell lysate in the experiments set forth below.

D) Immunoprecipitation

Immunoprecipitation was performed for the cell lysate obtained as above paragraph C, with an anti-LAR E-subunit antibody (a mixture of 7.5 µg of 11-1A and 7.5 µg of 75.3A, see, Streuli M. *et al.*, *EMBO J.*, **11**, 897-907, 1992). To 1 ml of the above cell lysis solution, 15 µg of MOPC 21 (mouse IgG1κ; Sigma Corporation) as a mock was added, then the solution was incubated at 4°C for one hour, added 20 µl of γ-bind (GammaBind Plus Sepharose; Pharmacia Biotech Inc.) thereto, and further incubated for one hour at 4°C to execute preabsorption. The solution was centrifuged at 4°C, 12,000 rpm for 10 minutes, then 950 µl of the supernatant was transferred to another tube. Next, 15 µg of anti-LAR E-subunit antibody was added to the supernatant, then the solution was incubated at 4°C for one hour, added 20 µl of γ-bind thereto, and further incubated for one hour at 4°C.

After centrifuge at 4°C, 12,000 rpm for 10 minutes, the precipitate was washed with 1 ml of lysis buffer twice, then once with PBS w/Inh., and suspended in 20 µl of SDS sample buffer. The suspension was heated for 5 minutes in a boiling water bath to prepare a sample for electrophoresis.

E) Immunoblotting

The above-mentioned sample was subjected to electrophoresis using 7.5% SDS-polyacrylamide gel, followed by transfer to a nitrocellulose membrane (Schleicher & Schuell) using a transfer device at 400 mA for 4 hours. Then blocking was conducted by incubating the membrane in 3% bovine serum albumin solution for longer than 30 minutes at a room temperature. After washing with sufficient volume of TBS-T (TBS with Tween 20: 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween 20) for 10 minutes more than twice, an anti-phosphotyrosine antibody (4G10, UBI) that was 50,000-fold diluted with TBS-T, the anti-LAR E-subunit antibody or an anti-insulin receptor β -chain antibody (UBI) was added thereto, then the mixture was shaken for one hour at a room temperature. After washing with sufficient volume of TBS-T for 5 minutes more than three times, 15 ml of TBS-T solution containing HRP-labelled anti-mouse IgG antibody (horseradish peroxidase-labelled anti-mouse IgG: Santa Cruz Biotechnology, Inc.) 1.5 ml was added thereto, and shaken for one hour at a room temperature. After washing with sufficient volume of TBS-T for 5 minutes more than three times, bands of the protein were detected that can bind to each of the antibodies, by means of chemiluminescence using a kit of luminescence reagents (Wako Pure Chemical Industries, Ltd.).

F) Results

As results of immunoblotting with the anti-phosphotyrosine antibody following to immunoprecipitation with the anti-LAR E-subunit antibody of cell lysate prepared after stimulation with insulin for determined time periods of cotransfected COS-7 cells with LAR C/S and IR WT in the above-described manner, tyrosine phosphorylation of an

insulin receptor β -chain as well as a 85 kDa protein could be observed with the insulin stimulation for 1 minute. Such tyrosine phosphorylation could also be successively observed with the insulin stimulation for 30 minutes (see, Fig. 2A).

Furthermore, results from the immunoblotting with the anti-LAR E-subunit antibody (Fig. 2B), the anti-insulin receptor β -chain antibody (Fig. 2C) and the anti-phosphotyrosine antibody (Fig. 2A) demonstrated that LAR and insulin receptor may associate depending on the presence or absence of tyrosine phosphorylation of the insulin receptor.

Experimental Example 2 Studies on tyrosine dephosphorylation of insulin receptor by various LAR (1)

Next, COS-7 cells were similarly cotransfected with LAR WT, LAR C/S or LAR DC/S, and IR WT followed by stimulation with insulin for 5 minutes, immunoprecipitation with the anti-LAR E-subunit antibody, and then immunoblotting with various types of antibodies for the precipitates was carried out. Consequently, tyrosine phosphorylation of the insulin receptor β -chain or the 85 kDa protein could not be detected for the cells cotransfected with insulin receptor and LAR WT, in comparison with the cells cotransfected with LAR C/S or LAR DC/S (see, Fig. 3A).

Additionally in these experiments, amounts of expression of LAR (Fig 3C) and the insulin receptor (Fig. 3D) were almost identical in both of the cotransfectants, therefore LAR WT was suggested to dephosphorylate the phosphorylated tyrosine of the insulin receptor β -chain as well as the 85 kDa protein (Fig. 3B).

Further, when the immunoprecipitates with the anti-LAR E-subunit antibody were immunoblotted using the anti-insulin receptor β -chain antibody, the cotransfectant with LAR DC/S showed a weaker band of an insulin receptor β -chain, compared to the cotransfectant with LAR WT or LAR C/S.

These results indicate that the association between insulin receptor and LAR DC/S is weaker, when compared with that of LAR WT or LAR C/S. The only one difference between LAR C/S and LAR DC/S is one amino acid residue position 1813 of phosphatase domain 2, accordingly, this domain 2, which was postulated to involve in binding with substrates without tyrosine phosphatase activity, was proved to be playing a role in binding between LAR and insulin receptor.

Experimental Example 3: Studies on tyrosine dephosphorylation of insulin receptor
by various LAR (2)

In order to further study as to whether tyrosine dephosphorylation of insulin receptor occurs only in cases where LAR was bound, or in every insulin receptor, cell lysate of the cotransfectant was subjected to electrophoresis, and then immunoblotted with the anti-phosphotyrosine antibody. Consequently, tyrosine dephosphorylation of insulin receptor was markedly found only in cells that had been cotransfected with LAR WT (see, Fig. 4).

Experimental Example 4: Studies on tyrosine phosphorylation of insulin receptor
in the presence of LAR C/S

In order to elucidate whether tyrosine phosphorylation of the 85 kDa protein is effected by a tyrosine kinase activity of insulin receptor, COS-7 cells were produced that were cotransfected with LAR C/S, and IR WT or IR K1018M(IR MT) having a deficiency in tyrosine kinase of insulin receptor. Following insulin stimulation of the cells for 5 minutes, immunoprecipitation was performed with the anti-LAR E-subunit antibody, and immunoblotting with the anti-phosphotyrosine antibody was carried out (see, Fig. 5). Consequently, the cells cotransfected with IR WT showed tyrosine phosphorylation of an insulin receptor β -chain and the 85 kDa protein upon stimulation with insulin, however, the

cells cotransfected with IR K1018M showed no such phosphorylation at all.

From these results, it was revealed that rapid tyrosine phosphorylation of insulin receptor occurs upon binding of insulin to insulin receptor; and that the insulin receptor tyrosine kinase leads tyrosine phosphorylation of the 85 kDa protein.

The 85 kDa protein was therefore speculated as a P-subunit of LAR of which binding to insulin receptor was demonstrated.

Example 1: Generation of antibodies to an intracellular domain of a LAR P-subunit

Antibodies to an intracellular domain of LAR were generated according to the following procedures.

A) Preparation of immunogen

Glutathione-S-transferase-LAR fusion protein (GST-LAR) was employed as an immunogen. *E. coli* AD202 was transformed with an expression vector, pGEX-2T vector (Pharmacia Biotech Inc.), which was incorporated to its *Bam*HI/*Eco*RI site with cDNA corresponding to 607 amino acids spanning from the end of a transmembrane region of a LAR P-subunit to the entire cytoplasmic region (SEQ ID NO. 1, 3467 bp) according to a general procedure. After the *E. coli* was incubated overnight in LB (Amp. +) agar medium (LB (Amp. +) described below containing 7.5 g of agar), single colony was inoculated to 50 ml of LB (Amp. +) medium (containing triptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, 5 N NaOH 0.2 ml/L, and ampicillin 50 µg / ml), and further incubated overnight. Then the *E. coli* was inoculated to 500 ml of LB (Amp. +) medium, and incubated at 37°C until absorbance at 600 nm reaches to approximately 1.0, followed by addition of 50 µl of 1 M IPTG (isopropyl-β-D(-)-thiogalactopyranoside, Wako Pure Chemical Industries, Ltd.) and an incubation at 25°C overnight. Thus resulted culture was centrifuged at 3,000 rpm, 4°C for 15 minutes, and the precipitated bacterial bodies were suspended in 50 ml of NETN (0.5 % Nonidet P-40, 1 mM EDTA, 20 mM Tris-HCl pH 8.0, 100 mM NaCl).

Thereafter, the suspension was subjected to twice repeated treatments of ultrasonication for 1 minute and standing on ice for one minute, and then centrifuged at 14,000 rpm, 4°C for 20 minutes to obtain the supernatant. To 10 ml of the lysate of the *E. coli*, 100 µl of suspension of glutathione sepharose beads (Glutathione Sepharose 4B (Pharmacia Biotech Inc.) that had been prepared by washing three times, and suspended in 50% NETN) was added, and then incubated for 30 minutes at a room temperature. Thus resulted suspension was centrifuged at 3,000 rpm, 4°C for 5 minutes, and supernatant was removed. The precipitated glutathione sepharose beads were washed twice with NETN, then once with PBS, thereafter 100 µl of SDS sample buffer (125 mM Tris-HCl pH 6.8, 0.1% sodium dodecylsulfate, 5% 2-mercaptoethanol) was added thereto, and heated in a boiling water bath for 10 minutes to elute the GST-LAR fusion protein. The eluate from which the beads were eliminated was concentrated by centrifuge using Centricon-10 (Amicon) at 3,000 rpm, 4°C for 45 minutes.

One ml of PBS was added to the concentrate in order to bufferize the solution, and the solution was concentrated again by centrifuge at 3,000 rpm, 4°C for 45 minutes. This process for bufferization was repeated twice, and thus resulted solution was employed as an immunogen solution. Purification and concentration of the antigenic protein were confirmed by SDS-polyacrylamide gel electrophoresis.

Meanwhile, on a final immunization, the antigen solution was prepared in a different process because it should be administered intravenously. The lysate of the above-described *E. coli* that is expressing GST-LAR fusion protein was incubated with glutathione sepharose beads, and after centrifuge, the precipitated beads were washed twice with NETN, and three times with PBS. Next, 100 µl of GSH elution buffer (20 mM glutathione, 1M Tris-HCl, pH 9.6) was added thereto, and the mixture was gently stirred for 10 minutes at a room temperature to accomplish the elution of GST-LAR. After repeating the steps of centrifuge at 3,000 rpm, 4°C for 5 minutes and recovering the supernatant

three times, the total eluate was dialyzed in saline at 4°C for 2 days, then thus obtained solution was employed as an immunogen solution for intravenous administration.

B) Immunization

Eight female Balb/c mice of 6 weeks old received intraperitoneal administration of pristane (2,6,10,14-tetramethylpentadecane, Sigma Corporation) at 0.5 ml/animal. After 2 weeks passed, the antigen solution for intraperitoneal immunization that was emulsified by blending with Freund's complete adjuvant (GIBCO) at a ratio of 1:1 was intraperitoneally administered at about 10 µg of GST-LAR fusion protein per one mouse. Thereafter, the antigen solution for intraperitoneal immunization that was admixed with Freund's incomplete adjuvant (GIBCO) at a ratio of 1:1 was prepared to be about 30-70 µg of GST-LAR per one mouse, and the mixture was intraperitoneally administered approximately once every 2 weeks. On day 4 after the fourth immunization, blood was collected from ocular fundus vein, and an antibody titer in the serum was determined by ELISA method.

C) ELISA

Protein solutions of GST-LAR and GST alone that were prepared similarly to the procedure of preparation of the antigen for intravenous immunization were respectively dialyzed against purified water at 4°C overnight. These solutions were adjusted to 0.5 µg/ml in PBS, and subjected to absorption to an ELISA plate (Falcon 3911 MicroTest™ Flexible Assay Plate) at 50 µl/well for one hour. After five times washes with wash buffer (PBS containing 0.05% Tween20), blocking with 5% skim milk (prepared by dissolving 2.5 g of skim milk in 50 ml of PBS) was conducted. Following washes, the serum as obtained in the above section B was diluted to 16,000 fold with dilution buffer (PBS containing 0.25% BSA), and was added to the wells at 50 µl/well, and then incubated for one hour in a wet box. After washing the plate, HRP-labelled anti-mouse IgG antibody that was diluted to 1,000 fold was added to the plate at 50 µl/well, and incubated for one

hour Following washes with wash buffer four times and once with PBS, a substrate solution of *o*-phenylenediamine (Wako Pure Chemical Industries, Ltd.) that was dissolved in a citrate buffer (prepared by dissolving 5.6325 g of citric acid monohydrate and 18.35 g of $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ in purified water to make 500 ml in total) at a concentration of 1 mg/ml was added at 50 μl /well, allowed for reaction for 30 minutes, and then 50 μl of 10% H_2SO_4 was added to terminate the reaction. Fifty μl of the solution was transferred to each well of a 96-well plate (Sumitomo Bakelite Co., LTD.) for measurement, and then absorbance at 450 nm was measured.

D) Cell fusion

Two mice that showed elevation of the antibody titers to GST-LAR in accordance with the results of the above ELISA were finally immunized, and spleen was excised therefrom on the third day to prepare splenocytes according to an ordinary procedure.

Parent cells employed for cell fusion were Balb/c mouse-derived myeloma cell strain NS1 that was previously selected in a medium containing 20 μg /ml 8-azaguanine, and confirmed as hypoxanthine, guanine, phosphoribosyl transferase (HGPRT) deficient strain. Cell fusion, HAT selection and cloning were performed with 2×10^7 of NS1 cells and 1×10^8 of splenocytes, using ClonaCellTM-HY Hybridoma Cloning Kit (StemCell Technologies Inc.).

Screening of the supernatant from the culture of the cloned hybridoma was carried out according to ELISA method described in section C above, with 50 μl of the supernatant of hybridoma culture using plates bound with 0.5 μg /ml protein solution of GST, GST-LAR or GST-CD45 (Furukawa, T *et al.*, *Proc. Natl. Acad. Sci. USA*, 91,10928-10932,1994) prepared by the similar method for preparation of the antigen for intravenous immunization as described above. In this ELISA method, hybridoma was selected, which did not show any immune response to the wells bound with GST or GST-CD45, but showed an immune response only to the wells bound with GST-LAR.

Passage culture of the cloned hybridoma was conducted with RPMI 1640 medium (Nissui Pharmaceutical Co., LTD) containing 10% fetal bovine serum (GIBCO)

Through screening by ELISA method of the culture supernatant in this manner from the hybridoma that was HAT selected, a clone YU1 having specificity to LAR intracellular domain, with stable antibody producibility and proliferation ability could be obtained.

This hybridoma cell line YU1 was deposited on May 7, 1998, with National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-1-320, Higashi, Tsukuba, Ibaraki, JAPAN, and assigned Accession No FERM BP-6343.

E) Typing of monoclonal antibody

Supernatant of 0.5 ml from culture of hybridoma YU1 obtained in the above section D was diluted with 4.5 ml of TBS-T, and isotype was determined for 3 ml of the diluted solution using mouse monoclonal antibody isotyping kit (Amersham International plc.). As a result, the isotype of the antibody was proved to be IgG2b.

F) Generation and purification of monoclonal antibody

Balb/c mice of 6 weeks old received intraperitoneal administration of pristane at 0.5 ml/animal, and after 10 days, hybridoma cell YU1 that was obtained by cloning in section D above was intraperitoneally injected at 2.5×10^6 - 1.3×10^7 cells/0.5 ml/animal. Abdominal hypertrophy was observed approximately 10 days thereafter, accordingly, ascites fluid was collected using a 20-gauge injection needle several times. Thus collected ascites fluid was centrifuged at 1,000 rpm, 4 °C for 5 minutes to separate supernatant and precipitate. The supernatant was incubated at 37 °C for 30 minutes, and stood at 4 °C overnight. Following centrifuge at 12,000 rpm, 4°C for 10 minutes, the monoclonal antibody YU1 was purified using an affinity column HiTrap ProteinG (Pharmacia Biotech Inc.) from the resulted 1.5 ml of supernatant. Concentration of the

antibody was calculated from molecular extinction coefficient of mouse IgG, based on the measured absorbance at 280 nm of the antibody solution thus obtained.

In addition, a molecular weight of the monoclonal antibody YU1 was estimated from mobility on SDS-polyacrylamide gel electrophoresis. The results are shown in Fig. 6. As is clear from the Fig. 6, monoclonal antibody YU1 comprises H-chain of about 50 kDa and L-chain of about 25 kDa, having a total molecular weight of about 150 kDa.

Example 2: Studies on specificity of monoclonal antibody

An expression vector of LAR WT was transfected into COS-7 cells according to the procedures described in Example 1, sections A and B. Following immunoprecipitation of the cell lysate with the purified monoclonal antibody obtained in Example 1, immunoblotting was carried out. As a control on immunoprecipitation, MOPC 21 for the antibodies belonging to IgG1 subclass (the anti-LAR E-subunit antibody (*supra*) and an anti-CD45 antibody (Santa Cruz Biotechnology, Inc., 35-Z6)), or mouse IgG2b κ (MOPC 195, CAPPEL) for the monoclonal antibody YU1 was employed.

From the analyses using the LAR enforced expression system in COS-7 cells, the monoclonal antibody YU1 recognized proteins of 85 kDa that corresponds to a LAR P-subunit and of about 200 kDa that corresponds to a precursor, after immunoprecipitation with the anti-LAR E-subunit antibody (see, Fig. 7B)

Moreover, upon immunoblotting with an antibody that recognizes a LAR E-subunit after immunoprecipitation of cell extract of COS-7 cells transfected with LAR using these antibodies (IgG1, IgG2b, or YU1), detection of proteins of 150 kDa that corresponds to a LAR E-subunit and of about 200 kDa that corresponds to a precursor was restricted only to that immunoprecipitated with the antibody YU1 (see, Fig. 7A). From the results above, it was revealed that the monoclonal antibody YU1 could be utilized for immunoprecipitation and immunoblotting of a LAR P-subunit.

Example 3. Phosphorylation of LAR by insulin receptor tyrosine kinase

Experimental Example 4 suggested a possibility that a tyrosine phosphorylated 85 kDa band that was detected with cotransfection of insulin receptor and LAR may be a P-subunit of LAR.

Accordingly, studies were conducted using the monoclonal antibody YU1, which was generated in Example 1, as to whether the 85 kDa protein of which tyrosine was phosphorylated by insulin receptor tyrosine kinase, was a LAR P-subunit according to a similar procedure described in Example 1.

Cell lysate of COS-7 cells stimulated with insulin for 1 minute following cotransfection of LAR WT or LAR C/S with IR, was immunoprecipitated with the anti-LAR E-subunit antibody, and then immunoblotted with a mixture of the anti-LAR E-subunit antibody and the antibody YU1, thus a precursor of LAR and each subunit were detected.

Further reprobe of this blot with the anti-phosphotyrosine antibody showed agreement of the 85 kDa tyrosine phosphorylated band with a band of a LAR P-subunit (see, Fig. 8). These results illustrate that LAR is one of the substrates of insulin receptor.

In addition, because the tyrosine phosphorylation of a LAR P-subunit was not detected for the cotransfectant with LAR WT, LAR was supposed to conduct autodephosphorylation (see, Fig. 3).

As shown in Fig. 9, when insulin binds to an insulin receptor α -chain, tyrosine kinase activity is elevated through autophosphorylation of the insulin receptor β -chain. This activity of tyrosine kinase finally results in occurrence of insulin actions such as glucose uptake, glucose metabolism, and cell proliferation. The activated insulin receptor was indicated to be back to an inactive state through tyrosine dephosphorylation by LAR.

Additionally, it was proved that insulin receptor kinase phosphorylates tyrosine of

a LAR intracellular domain, and the phosphorylation was speculated to participate in determination of substrate specificity of the LAR intracellular domain or elevation of phosphatase activity. Besides, LAR is conceived as controlling its enzymatic activity through autodephosphorylation of the phosphorylated tyrosine.

From the results set forth above, possibility could be illustrated on a molecular level, that stimulation of enzymatic activity of LAR may be responsible for insulin resistance

Example 4: Tissue distribution of LAR in mouse

To one gram of each of the organs that were excised from male C57BL/6 mouse of seven weeks old was added with 3 ml of cold cell lysis buffer (the same buffer as described in Experimental Example 1, section C) followed by homogenization on ice, and incubation for 30 minutes on ice. After centrifuge at 4°C, 15,000 x g for 20 minutes, the supernatant was recovered, additionally obtained supernatant by the same centrifuge condition was recovered, then total supernatant was employed as a tissue sample. Protein determination was performed according to a manual of DC Protein Assay (Bio-Rad).

Thus obtained each supernatant (corresponding to 0.2 mg of protein) was electrophoresed, followed by immunoblotting with YU1 according to a procedure described in Experimental Example 1, E.

The results of the immunoblotting are shown in Fig. 14. YU1 can also recognize mouse LAR, thereby expression in thymus and brain could be identified. Slight expression could be found in kidney and liver as well.

Example 5: Immunohistochemical staining of thyroid carcinoma tissue section with YU1

Thyroid tissue was fixed in 10% neutral phosphate buffered formaldehyde solution, and embedded in a paraffin block to prepare a specimen on a slide. The

detailed procedures are described below

1) Deparaffination

The fixed paraffin block of the tissue section was immersed in 100% xylene for 5 minutes twice, and then serially immersed in 100% ethanol, 90% ethanol, and 70% ethanol for 3 minutes respectively. Finally, the section was immersed in 10 mM citrate buffer (pH 6.0). In order to make antigen determinants exposed in this state, the specimen was subjected to an autoclave treatment at 100°C, for 5 minutes.

2) Immunostaining

The section was washed with 50 mM Tris-HCl buffer (pH 7.6) containing 0.15M NaCl (Tris solution), and then immersed in this Tris solution. Thereafter, the liquid was wiped away from the slide glass, then the section was dropped with 3% aqueous hydrogen peroxide, and stood for 3 minutes in order to eliminate endogenous peroxidase.

Following sufficient washes with water and additional sufficient washes with Tris solution, the excess liquid was wiped away, and the section was incubated with 50 mM Tris-HCl buffer (pH 7.6) solution containing a carrier protein (2% BSA), 0.015M sodium azide and 0.15M NaCl for 15 minutes to effect blocking.

Next, after the excess liquid was wiped away without washing, primary antibody YU1 (1000 fold dilution of the stock solution) was added on the section, and incubated for 90 minutes in a wet box.

The tissue section was then washed sufficiently with 50 mM Tris-HCl buffer (pH 7.6) containing 0.15M NaCl, and secondary antibody (biotinylated anti-mouse immunoglobulin) was added, followed by incubation for 45 minutes.

Thereafter, the section was sufficiently washed with 50 mM Tris-HCl buffer (pH 7.6) containing 0.15M NaCl, dropped with streptavidin conjugated horseradish peroxidase, and then stood for 25 minutes.

Next, after sufficient washes of the section with 50 mM Tris-HCl buffer (pH

Amended under PCT Art. 34(2)(b)

7.6) containing 0.15M NaCl, then 0.05% DAB (3,3'-diaminobenzidine tetra-hydrochloride) solution in 50 mM Tris-HCl buffer (pH 7.6) containing 0.02% hydrogen peroxide and 0.15M NaCl was added, followed by confirmation of color development under microscopy, and then the reaction was terminated by immersion of the slide glass into water.

Following termination of the reaction, the specimen was soaked in Mayer's hematoxylin for 5-10 seconds for counter staining. Thereafter, followed by washes of the specimen with water, and soaking in 100% ethanol for 1 minute twice, next in 100% xylene for 1 minute twice, inclusion with Malinol and observation were carried out.

In these experiments, blocking, secondary antibody, and streptavidin-peroxidase solutions were from LSAB kit available from DAKO Japan Co. Ltd., (Kyoto), and DAB was a commercially available reagent from Dojindo (Kumamoto), Malinol was from Muto Pure Chemicals Ltd., (Tokyo), and Mayer's hematoxylin employed was prepared by the present inventor.

Thus resulted immunohistochemical staining of thyroid papillary carcinoma cells are shown in Figures 11-13. These Figures demonstrate selective reactivity of YU1 antibody to thyroid carcinoma cells (brown color stained part), without any reactivity to normal follicular cells and stroma of tumor tissue (blue color stained part).

Accordingly, it was proved that diagnosis of thyroid carcinoma using immunohistochemical staining with the present antibody can be accomplished, and that the present antibody can also be useful in a DDS system comprising anticancer agents (chemotherapeutic agents).

Example 6: Immunohistochemical staining of another benign tumor cells and carcinoma cells

Amended under PCT Art. 34(2)(b)

According to the similar procedure in Example 5, immunostaining of various benign tumor and carcinoma cells (that were derived from human) shown in Table 1 below was examined.

Positive results were estimated as appearances of staining based on reactivity to YU1 antibody, and each positivity is presented in Table 1 below.

Table 1

Tumor		Number Of Cases	Number of Positive Cases	Positivity
Benign	Meningioma	10	0	0
	Thyroid adenoma	10	0	0
Malignant	Thyroid carcinoma	21	21	100
	Glioma	13	1	7.7
	Gastric carcinoma	16	1	6.3
	Colon carcinoma	26	13	50
	Lung carcinoma	20	2	10
	Breast carcinoma	20	3	15
	Liver carcinoma	8	0	0
	Kidney carcinoma	21	0	0
	Prostate carcinoma	32	2	6.3

Consequently, it was obviously shown that the positivity in thyroid carcinoma was 100%, to the contrary, benign tumor and carcinoma originated from another organs showed lower positivity or completely negative. Although comparative

Amended under PCT Art. 34(2)(b)

higher positivity was shown in colon cancer, normal grandular epithelia were also weakly positive, therefore, positive staining presented in colon carcinoma was distinct from that in thyroid carcinoma, accordingly, specific immunoreactivity of YU1 to thyroid carcinoma cells was suggested, with which remarkable staining were observed.

Example 7: Specific immunoreaction of thyroid carcinoma with YU1:

Studies on feasibility of utilizing immunoassays

To one gram of human thyroid carcinoma and normal tissues that were used in Example 5, 3 ml of cold cell lysis buffer (set forth above in Example 5) was added, and homogenized using Polytron, thereafter, the homogenate was incubated for 30 minutes on ice. Following centrifuge at 4°C, 15,000 x g for 20 minutes, the supernatant was recovered, and additionally obtained supernatant by the same centrifuge condition was recovered, then total supernatant was employed as a tissue sample. Protein determination was performed according to a manual of DC Protein Assay (Bio-Rad).

Thus obtained supernatant (corresponding to 1 mg of protein), or immunoprecipitates of COS-7 cells transfected with LAR using the anti-LAR antibody as a positive control (prepared according to the procedures in Example 1A-C) were electrophoresed, followed by immunoblotting with YU1, according to a procedure described in Experimental Example 1, section E. For detection, Immuno Star Reagents (Wako Pure Chemical Industries, Ltd.) was employed.

The results obtained in these experiments are shown in Fig. 10. As is clear from Fig. 10, it was evident that YU1 specifically recognizes the thyroid carcinoma cells, distinct from the normal thyroid cells. Accordingly, it was proved that tissue samples obtained in fine needle aspiration cytology of thyroid could be utilized for diagnosis of thyroid cancer.

Amended under PCT Art. 34(2)(b)

INDUSTRIAL APPLICABILITY

The antibodies to a LAR phosphatase subunit that is provided by the present invention can specifically recognize an intracellular domain of LAR having phosphatase activity. Therefore, the antibodies can be extremely useful tools for elucidating signal transduction mechanisms of insulin, and for identifying, obtaining LAR modulators, binding proteins, and the like. Furthermore, the antibodies can be applied for developing useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onset of arteriosclerosis and cardiac diseases.

Additionally, because the antibodies of the present invention have specific immunoreactivity to thyroid carcinoma, they are useful in diagnosis of thyroid carcinoma using fine needle aspiration cytology or tissue sections, and in pharmaceutical compositions that utilize DDS for thyroid carcinoma therapy, while they can be helpful to molecular biological studies on transcription of LAR molecules in thyroid carcinoma cells and regulation factors of expression at a translational level.

What is claimed is:

1. An antibody having specificity to a LAR phosphatase subunit.
2. An antibody having specificity to an intracellular domain of a LAR phosphatase subunit.
3. An antibody having specificity to an intracellular domain of a LAR phosphatase subunit, and having no specificity to CD45.
4. The antibody according to any of claims 1-3, which is generated using a polypeptide encoded by a base sequence set out in SEQ ID NO: 1 or a fragment of said polypeptide as an antigen.
5. The antibody according to any of claims 1-4 wherein the antibody is a monoclonal antibody.
6. The antibody according to any of claims 1-5 wherein the antibody is generated using a fusion protein comprising a LAR phosphatase domain and another protein or a polypeptide fragment as an immunogen.
7. The antibody according to any of claims 1-5 wherein the antibody is generated using a GST-LAR phosphatase domain fusion protein as an immunogen.
8. The antibody according to claim 7 wherein the GST-LAR phosphatase domain fusion protein is produced by: culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours; and isolating the fusion protein from the culture fluid and/or bacterial cells.
9. The antibody according to claim 8 wherein the GST-LAR phosphatase domain fusion protein is further purified based on an affinity to a support carrying glutathione wherein the elution of said fusion protein from the support is performed by boiling in the presence of a detergent.
10. The antibody according to any of claims 6-9 wherein the antibody that

was generated using the fusion protein as an immunogen is screened using said fusion protein.

11 A monoclonal antibody having specificity to a LAR phosphatase subunit, which is produced by a hybridoma with Accession No FERM BP-6343

12 The antibody according to any of claims 5-11 having a molecular weight of about 150 kDa

13. A hybridoma cell line that produces the antibody according to any of claims 5-10 and 12.

14. A hybridoma cell line with Accession No. FERM BP-6343.

15. A method for generating an antibody having specificity to a LAR phosphatase subunit wherein a fusion protein comprising a LAR phosphatase domain and another protein or a polypeptide fragment is used as an immunogen.

16. A method for generating an antibody having specificity to a LAR phosphatase subunit wherein a GST-LAR phosphatase domain fusion protein is used as an immunogen.

17. The method according to claim 16 wherein the GST-LAR phosphatase domain fusion protein is produced by culturing *Escherichia coli* transformed or transfected with an expression vector comprising a coding region of GST gene and a coding region of a phosphatase domain of LAR gene at 20-30°C for 16-24 hours, and isolating the fusion protein from the culture fluid and/or bacterial cells.

18. The method according to claim 17 wherein the GST-LAR phosphatase domain fusion protein is further purified based on an affinity to a support carrying glutathione wherein the elution of said fusion protein from the support is performed by boiling in the presence of a detergent.

19. The method according to any of claims 15-18 wherein the antibody that was generated using the fusion protein as an immunogen is screened using said

fusion protein.

20 A method of quantitative determination of LAR and/or LAR derived molecules comprising the step of

determining an amount of LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain, which is contained in a test sample using the antibody according to any of claims 1-12.

21. The method according to claim 20 wherein the antibody is used in any of immunoblotting, immunoprecipitation and ELISA.

22. A method for quantitative determination of LAR and/or LAR derived molecules comprising the steps of:

isolating LAR and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain, from a test sample using the antibody according to any of claims 1-12; and

measuring an activity of the isolated LAR and/or LAR derived molecules.

23. The method according to claim 22 wherein affinity chromatography and/or immunoprecipitation by using a support that was bound with the antibody are utilized in the isolation step.

24. A method for producing LAR and/or LAR derived molecules comprising the step of:

isolating LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain using the antibody according to any of claims 1-12.

25. The method according to claim 24 wherein affinity chromatography and/or immunoprecipitation by using a support that was bound with the antibody are utilized in the isolation step.

26 A method for identifying the presence of LAR and/or LAR derived molecules within tissue comprising the step of:

performing immunohistological examination using the antibody according to any of claims 1-12 to detect LAR protein and/or a fragment or a polypeptide that comprises at least a LAR intracellular domain.

27. An anti-LAR antibody having specific immunoreactivity to thyroid carcinoma cells.

28. The antibody according to any of claims 1-12 having specific immunoreactivity to thyroid carcinoma cells.

29. A method for diagnosis of thyroid carcinoma comprising the steps of:
taking a thyroid tissue specimen from a subject suspected as suffering from thyroid cancer; and

conducting diagnosis of thyroid cancer through evaluating immunoreactivity between the antibody according to claim 27 or 28 and said tissue specimen.

30. The method according to claim 29 wherein the thyroid tissue specimen is a specimen that is taken by fine needle aspiration, and the immunoreactivity is evaluated by an immunoassay.

31. The method according to claim 29 wherein the thyroid tissue specimen is a thyroid tissue section, and the immunoreactivity is evaluated by histological staining.

32. A composition for histological diagnosis of thyroid carcinoma comprising the antibody according to claim 27 or 28.

33. A DDS formulation that was targeted to thyroid carcinoma cells using the antibody according to claim 27 or 28.

34. The DDS formulation according to claim 33 comprising one or more materials which are selected from a group consisting of a nucleic acid, iodine, radioactive iodine, technetium and a protein.

35. The DDS formulation according to claim 33 or 34 which is a pharmaceutical composition for diagnosis of thyroid carcinoma.

36. The DDS formulation according to claim 33 or 34 which is a pharmaceutical composition for therapy of thyroid carcinoma.

37 The DDS formulation according to claim 36 further comprising an anticancer agent.

38. The DDS formulation according to claim 36 or 37 wherein the nucleic acid is an antisense nucleic acid or a ribozyme.

39. A diagnostic method of thyroid carcinoma wherein a probe for LAR mRNA is used.

ABSTRACT

Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.





Fig. 1

Publ. No. 09/719272




Fig.2




Fig.3




Fig. 4




Fig. 5




Fig. 6

7/14




Fig.7




Fig.8




Fig. 9

09/719272

WO 99/64591

10/14

PCT/JP99/03054
Amended under PCT Art.34(2)(b)




Fig. 10

10n7

WO 99/64591

09/719272

PCT/JP99/03054

Amended under PCT Art.34(2)(b)

11/14



Fig.11




Fig.12




Fig.13

14 / 14




Fig. 14

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "ANTIBODIES SPECIFIC FOR PHOSPHATASE SUBUNIT FOR LAR," the specification of which was transmitted to the United States Receiving Office on December 8, 2000 as Application Serial No. 09/719,272 as U.S. National Phase of PCT International Application No. PCT/JP99/63054, filed June 7, 1999, which was amended by Preliminary Amendment dated December 8, 2000, and by Second Preliminary Amendment dated January 10, 2001. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Priority Claimed

<u>PCT/JP98/02542</u>	<u>Japan</u>	<u>08 June 1998</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

<u>None</u>	
(Application Serial Number)	(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

<u>None</u>		
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Allen H. Gerstein (22,218)
Nate F. Scarpelli (22,320)
Edward M. O'Toole (22,477)
Michael F. Borun (25,447)
Trevor B. Joice (25,542)
Carl E. Moore, Jr (26,487)
Richard H. Anderson (26,526)

Patrick D. Ertel (26,877)
James P. Zeller (28,491)
William E. McCracken (30,195)
Richard A. Schnurr (30,890)
Anthony Nimmo (30,920)
Christine A. Dudzik (31,245)
Kevin D. Hogg (31,839)

Jeffrey S. Sharp (31,879)
Martin J. Hirsch (32,237)
James J. Napoli (32,361)
Richard M. La Barge (32,254)
Li-Hsien Rin-Laures, M.D. (33,547)
Douglass C. Hochstetler (33,710)
Robert M. Gerstein (34,824)

David W. Clough (36,107)
Anthony G. Sitko (36,278)
James A. Flight (37,622)
Roger A. Heppermann (37,641)
David A. Gass (38,153)
Gregory C. Mayer (38,238)
Michael R. Weiner (38,359)
William K. Merkel (40,725)

Send correspondence to: David A. Gass

FIRM NAME	PHONE NO	STREET	CITY & STATE	ZIP CODE
Marshall, O'Toole, Gerstein, Murray & Borun	312-474-6300	6300 Sears Tower 233 South Wacker Drive	Chicago, Illinois	60606-6402

Full Name of First or Sole Inventor Hiroshi Yamamoto	Citizenship Japanese
Residence Address - Street 11-1-103, Sakuranochi 7-chome, Toyonaka-shi	Post Office Address - Street 11-1-103, Sakuranochi 7-chome, Toyonaka-shi
City (Zip) Osaka 560-0054	City (Zip) Osaka 560-0054
State or Country Japan JPK	State or Country Japan
Date <input checked="" type="checkbox"/> January 29, 2001	Signature <input checked="" type="checkbox"/> <i>Hiroshi Yamamoto</i>

Second Joint Inventor, if any Kazutake Tsujikawa	Citizenship Japanese
Residence Address - Street 11-7, Keyakizaka 3-chome, Kawanishi-shi	Post Office Address - Street 11-7, Keyakizaka 3-chome, Kawanishi-shi
City (Zip) Hyogo 666-0145	City (Zip) Hyogo 666-0145
State or Country Japan JPK	State or Country Japan
Date <input checked="" type="checkbox"/> January 29, 2001	Signature <input checked="" type="checkbox"/> <i>Kazutake Tsujikawa</i>

Third Joint Inventor, if any Yukiko Uchino	Citizenship Japanese
Residence Address - Street 15-20-213, 1-chome, Komatsu, Higashiyodogawa-ku, Osaka-shi	Post Office Address - Street 15-20-213, 1-chome, Komatsu, Higashiyodogawa-ku, Osaka-shi
City (Zip) Osaka 533-0004	City (Zip) Osaka 533-0004
State or Country Japan JPK	State or Country Japan
Date <input checked="" type="checkbox"/> January 29, 2001	Signature <input checked="" type="checkbox"/> <i>Yukiko Uchino</i>

Fourth Joint Inventor, if any Noboru Konishi	Citizenship Japanese
Residence Address - Street 7-8-17, Shirakashi-cho, Kashihara-shi	Post Office Address - Street 7-8-17, Shirakashi-cho, Kashihara-shi
City (Zip) Nara 634-0051	City (Zip) Nara 634-0051
State or Country Japan JPK	State or Country Japan
Date <input checked="" type="checkbox"/> January 29, 2001	Signature <input checked="" type="checkbox"/> <i>Noboru Konishi</i>

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.